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This report discusses our Company’s sustainability activities and 
progress as of December 2008. It is our sixth annual Sustainability Report 
and the 12th year we are reporting on our environmental progress. 
In developing this report, we have considered employee and external 
feedback on the 2007 report. The feedback was derived from our 
contact mailbox (csr@its.jnj.com), multiple stakeholder engagements, 
senior company leadership input and comments received from 
SustainAbility Inc., an expert  consultancy in sustainability reporting.
About This Report
  Our 2008 report begins with a 
comprehensive discussion of who we are, 
what we do, how we operate our business 
and a summary of our sustainability strategy 
and 2008 highlights. This is followed by a 
concise discussion of our environmental, 
social and economic performance as guided 
by Our Credo. The report is augmented by 
information contained on our website, 
www.jnj.com. The primary audience for 
this report is external stakeholders, a broad 
and diverse group. The Company has other 
mechanisms for sharing sustainability 
progress internally.
 Data presented throughout the report 
typically represents the manufacturing 
and research and development facilities 
operated by the Johnson & Johnson Family 
of Companies. No external manufacturing 
is included in our data. As we engage further 
with our supply chain on sustainability topics, 
additional information on these eﬀ orts may 
be included in future reports. 
 Changes during the reporting period 
were related to previously announced 
restructuring activity as well as acquisitions 
and divestitures. With the exception of 
the divestiture of the Professional Wound 
Care business of Ethicon, Inc.—which 
resulted in a gain of $536 million before 
tax and is recorded in other (income) 
expense, net, in 2008—divestitures in 
2008 did not have a material eﬀ ect on the 
Company’s results of operations, cash ﬂ ows 
or ﬁ nancial position. For further details 
about these changes, please see sections 
on Mergers, Acquisitions and Divestitures, 
and Restructuring in our 10-K Annual 
Report, available at www.investor.jnj.com/
governance/sec-ﬁ lings.cfm. 
 There have been no signiﬁ cant changes 
from previous reporting periods in the scope, 
boundary or measurement methods applied 
in this report. 
GLOBAL REPORTING INITIATIVE (GRI)
We approached the report somewhat 
diﬀ erently this year, hoping to achieve a 
greater level of transparency and facilitate 
engagement on a broader number of 
performance indicators. Topics were 
selected based on issues identiﬁ ed as 
important to our business and industry 
sector, based on an internal and external 
review and discussions conducted for this 
purpose. Additionally, consideration was 
given to the Global Reporting Initiative’s 
2006 Sustainability Reporting Guidelines 
(G3 Guidelines), and GRI indicators were 
considered in determining the report content. 
 Our data collection and management 
process continues to evolve, balancing 
the need for enterprise-wide information 
with our philosophy of local company 
accountability. We continue to evolve 
our materiality assessment process, in 
consideration of preparing this report in a 
formal GRI format. At the end of this report 
we have included an index with references to 
G3 indicators. 
F E E D B A C K
We invite you to  comment on our 
sustainability activities and this report by 
emailing us at csr@its.jnj.com. 
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O N  T H E  C O V E R  After climate change, water may be the world’s most pressing environmental 
challenge. Clean water—and enough of it—is among the bigger-picture environmental impacts 
we consider as part of our corporate citizenship. Employees like Mladen Loncar, Project Manager 
with Global Pharmaceutical Supply Group at Cilag AG in Switzerland, plan and implement eﬀ orts 
to reuse or recycle water in our facilities as part of a comprehensive water-management strategy. 
See “Keeping Water Vital” on page 20.
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Message From the Chairman
Caring for the world . . . one person at a time
 We aim to make the world a better and 
healthier place through everything we do—
the businesses we pursue, the products we 
discover and develop, the philanthropy we 
give, and the programs and alliances we build 
and join. Our mission is reﬂ ected in the way 
we run our businesses around the world, 
every day. Our approach to corporate 
citizenship deﬁ nes who we are and how we 
aspire to act in the world. It is rooted in an 
enduring appreciation of true sustainability. 
OUR REPORTING PRIORITIES
We see corporate citizenship, or 
sustainability, not as a set of “add-ons” to our 
business but rather as intrinsic to everything 
we do. We’ve long recognized that the 
sustainability of our business depends on 
being attuned to society’s expectations 
across many domains—including the 
environment, access to medicines, advocacy, 
governance and compliance. In all these 
areas and more, we ﬁ nd the engagement of 
stakeholders invaluable. We support and 
partner with them.  More important, we 
listen to and learn from them.
 Stakeholders have asked us to be more 
speciﬁ c about the social aspects of our 
sustainability, as well as measures we use to 
assess our progress. With this report, and 
with accompanying information that will be 
placed on our websites, we are embarking on 
a path of providing more information.  We do 
not expect to achieve all this in one report, 
but we do expect to make good progress.  
 Our report this year will give you a sense 
of the challenges and opportunities before 
Johnson & Johnson and help you understand 
the approaches we are taking, the goals and 
priorities we’ve set, and the impact of our 
performance. This expanded data may still 
not meet the preferences and requests of 
all stakeholders. We acknowledge that 
there’s more to do, and we’re working to 
provide additional performance reporting 
for the future.
ASSESSING OUR IMPACTS
After assessing various matters that could 
impact our ability to execute our business 
strategy, the degree to which our Company 
can impact these matters, and what we have 
heard from stakeholders, we believe there 
are several areas that could impact 
sustainability for Johnson & Johnson. 
These include:
• Researching, developing and bringing to 
market new medicines, medical devices and 
diagnostics that address unmet medical 
needs and new consumer products that 
improve health and well-being
• Enhancing access to our health care 
products
• Conducting our business to the highest 
ethical standards
• Ensuring the quality and safety of our 
products
• Managing our environmental impacts
Each of these is intrinsic to our success.
BRINGING NEW PRODUCTS TO MARKET
Like all health care companies, we face 
important challenges to innovation that 
reﬂ ect the increasing demand for health 
care around the world. In the U.S. and 
other nations, payers are seeking to reform 
health care and reduce costs. Some of 
these approaches could have a negative 
impact on the ability of research-intensive 
companies to bring innovative products to 
patients and customers. We are working 
closely with governments and other 
stakeholders to address these issues 
through creative policy approaches. For 
more information about our views on 
health care policy, see page 8. 
 We also face competitive pressures, 
patent expirations and a slower economy. 
We have successfully managed for these 
changes and delivered solid growth in 2008. 
In addition, we have strengthened our core 
franchises and built a robust pipeline of 
new medicines. Even as we grow our 
business in several new directions, we have 
maintained our ﬁ nancial strength with 
strong cash ﬂ ows and a triple-A credit 
rating. We have also made cost structure 
improvements that will help us operate 
more eﬃ  ciently.
 Despite challenges, we see enormous 
opportunity for continued growth. One 
area discussed in this report is wellness 
and prevention, where we are pioneering 
an exciting new business area for 
Johnson & Johnson. An aging population is 
creating high demand for both preventive 
services and health care. Another area we 
discuss here is growth in emerging markets, 
where we are building capacity and 
developing products speciﬁ cally designed 
for these markets. Against all these issues, 
we believe we made good progress in 
bringing important new products to market 
in 2008.
Over the past 20 years, the idea of a triple bottom line has emerged as a 
framework for reporting a company’s sustainability—its total impact on the 
world. This idea has been succinctly expressed as “People. Planet. Proﬁ t.” 
But more than 65 years ago—long before “triple bottom line” was a reporting 
goal—Our Credo oﬀ ered Johnson & Johnson a business philosophy that 
continues to drive a deep commitment to operating sustainably. 
W I L L I A M  C .  W E L D O N 
Chairman, Board of Directors, 
and Chief Executive Oﬃ  cer
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ENHANCING ACCESS
Access to our medicines is more than a
philanthropic obligation. If patients do not
have access, our work of developing new
medicines, devices and diagnostics does not
meet its goal. Among our eﬀ orts to increase
access, we:
• Advocate for enhanced access through
health care coverage and participate in many
coalitions in the U.S. and elsewhere to
improve access to care;
• Oﬀ er reduced pricing based on local
market conditions;
• Work with key public-private partnerships
to bring important new medicines to
patients in the developing world;
• Collaborate with generic manufacturers to
ensure our HIV medicines reach patients in
those countries;
• Support access programs both in the U.S.
and through our Global Access Program.
Our access eﬀ orts demonstrate that
patents need not be a barrier to access. We
believe we have made good progress in
enhancing access (discussed on pages 8
and 30), and we expect to expand our global
eﬀ orts in the future.
ETHICAL BEHAVIOR
Conducting our business to the highest
ethical standards is a cornerstone of our
commitment to putting patients ﬁ rst.
Our Credo attracts people who are
committed to making a positive diﬀ erence
in the world, and we provide them with
comprehensive systems that support
ethical behavior and compliance with laws
and regulations. We have a solid
compliance organization with a Health
Care Compliance Oﬃ ce and a Chief
Compliance Oﬃ cer. This oﬃ ce provides
oversight at the corporate level, in addition
to the many compliance units in our
businesses around the world.
In 2008, new sales and marketing
codes were implemented in the U.S.
pharmaceuticals and medical devices and
diagnostics businesses, as was a new
direct-to-consumer communications code.
In addition, the U.S. pharmaceuticals and
medical devices and diagnostics businesses
are now posting educational grants and
charitable contributions on their websites
and have committed to post their payments
to physicians by June 2011. We’ve listed
many of our policies and codes of behavior
on page 10. Our progress in this area in
2008 was good.
QUALITY & SAFETY
Ensuring the quality and safety of our
products is a hallmark of the trust our
customers and patients place in us. Every
product we sell must meet high standards,
and our products are assessed at each major
stage of their lifecycle (see page 12).
 Even so, new information about rare side
eﬀ ects or reactions may emerge only after
a product is used in large populations.
We have worked with others to educate
policymakers and the public about the
importance of understanding the risks of
treatment in the context of beneﬁ ts. It is
only by seeing both risks and beneﬁ ts that
good clinical decisions can be made and
optimal outcomes achieved.
In addition to working to ensure the
safety of our ﬁ nished products, we also
carefully evaluate component ingredients
and materials. We made good progress in
2008 in further enhancing our quality and
safety programs.
PROTECTING THE ENVIRONMENT
Our accountability for managing
environmental impacts has grown since
1990, when we began setting long-term
goals to help us reduce our environmental
footprint. Our progress in meeting each of
these goals has been good and is discussed
on pages 22–25. We’re now drawing to the
end of the current Healthy Planet 2010 goal
period, and we’re actively developing our
next set of goals. To guide our goal-setting
process, we are seeking input from
stakeholders, including government
oﬃ cials, environmental groups, other
companies and academic thought leaders.
For additional information on any of the
topics covered in this report, visit our
website.1 This year we have keyed our report
topics to the Global Reporting Index and
have included in the index at the back of this
book speciﬁ c links to jnj.com and other
Johnson & Johnson publications.
Our corporate citizenship is about doing
the right thing in all aspects of our business
and in every way we touch the world. That’s
what has always inspired our people, and
that’s what deﬁ nes our culture of caring for
the world, one person at a time. We are
committed to advancing our business and,
through it, the health and well-being of
people everywhere.
William C. Weldon
Chairman, Board of Directors,
and Chief Executive Oﬃ cer
June 1, 2009
We aim to make the world
a better and healthier
place through everything
we do—the businesses we
pursue, the products we
discover and develop, the
philanthropy we give, and
the programs and alliances
we build and join. Our
mission is reﬂ ected in the
way we run our businesses
around the world, every day.
This report contains “forward-looking statements” as
deﬁ ned in the Private Securities Litigation Reform Act
of 1995. These statements are based on current
expectations of future events. If underlying
assumptions prove inaccurate or unknown risks or
uncertainties materialize, actual results could vary
materially from Johnson & Johnson’s expectations
and projections. Risks and uncertainties include
general industry conditions and competition;
economic conditions, such as interest rate and
currency exchange rate ﬂ uctuations; technological
advances and patents attained by competitors;
challenges inherent in new product development,
including obtaining regulatory approvals; domestic
and foreign health care reforms and governmental
laws and regulations; and trends toward health care
cost containment. A further list and description of
these risks, uncertainties and other factors can be
found in Exhibit 99 of the Company’s Annual Report
on Form 10-K for the ﬁ scal year ended December 28,
2008. Copies of this Form 10-K, as well as subsequent
ﬁ lings, are available online at www.sec.gov, www.jnj.
com or on request from Johnson & Johnson.
Johnson & Johnson does not undertake to update any
forward-looking statements as a result of new
information or future events or developments.
1 www.jnj.com/connect/about-jnj/views-positions.
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OUR 2008 SUCCESSES
SOCIETY
• Began disclosing, on our operating 
company websites, grants for professional 
education and charitable contributions 
made by our U.S. pharmaceutical companies. 
Our U.S. medical devices and diagnostics 
companies followed in 2009. 
• Signed a royalty-free license agreement 
with Emcure, a generic drug manufacturer 
in India, to register, package and distribute 
our HIV/AIDS medicine, darunavir (known 
as PREZISTA®  in many markets) under 
Emcure’s trade name in many least-
developed markets at a substantially lower 
price than developed-world prices. 
• Implemented new sales and marketing 
codes in the U.S. pharmaceuticals and 
medical devices and diagnostics businesses. 
Also established new direct-to-consumer 
communications codes in these businesses.1
• Gave more than 156,000 needy patients 
in the U.S. more than 878,000 units of our 
prescription medicines without charge 
through our Patient Assistance Program. 
• Among our many contributions programs, 
worked with humanitarian relief partners 
to provide health care services and clean 
water to displaced people in Darfur, Sudan; 
provided medical mission packs in support 
of medical missions under the direction of 
MAP International; and supported more 
than 100 HIV/AIDS philanthropy programs 
in over 50 countries. 
ENVIRONMENT 
• Reduced carbon dioxide emissions at 
all company-owned facilities as well as 
larger leased facilities by 9 percent on an 
absolute basis when compared to 1990, 
while worldwide sales rose by more than 
400 percent.
• Obtained 34 percent of the electricity used 
by our companies from renewable resources.
• Reduced hazardous and non-hazardous 
waste generation in our company-owned 
facilities by 16 percent from 2005–2008. 
• Amassed more than 2,100 hybrid vehicles 
in our U.S.-based ﬂ eet, making ours the top 
commercial hybrid ﬂ eet in the United States. 
• Developed a new product lifecycle, 
designed to help our companies identify 
ways to green their products. 
BUSINESS
• Delivered on our economic commitments 
and ﬁ nished the year as the third-best- 
performing stock in the Dow Jones 
Industrial Average, despite increased generic 
competition worldwide, patent expirations 
and some of the most challenging global 
economic conditions in 80 years.
• Completed the successful acquisitions of 
HealthMedia, Inc. and Human Performance 
Institute, Inc., which deliver unique 
technologies in the growing areas of wellness 
and prevention;  Mentor Corporation, a 
leading supplier of medical products for 
the global aesthetic market; and Omrix 
Biopharmaceuticals, Inc., a company 
focused on the hemostasis market.
• Streamlined our cost structure, generating 
$1.6 billion in annual savings in just our 
pharmaceutical and Cordis Inc. businesses. 
And we are on track to realize $500 million 
to $600 million in synergies from the Pﬁ zer 
Consumer Healthcare acquisition.
• Repurchased more than $8.1 billion of 
Johnson & Johnson stock. 
• Invested $7.6 billion in research & 
development, yielding strong pipeline 
results, including ﬁ ve ﬁ lings and two drug 
approvals. 
• Sponsored the 2008 Beijing Olympic and 
Paralympic Game as an Oﬃ  cial Partner 
of the Games, a worldwide partner of the 
International Olympic Committee and the 
Oﬃ  cial Health Care Products Partner of 
National Olympic Committees in more than 
200 countries. 
• Was an originating partner, together 
with the American Medical Association 
and others, in developing the Health Care 
Notiﬁ cation Network, which provides U.S. 
doctors with rapid electronic versions of 
FDA-required patient safety alerts.
OUR CHALLENGES
SOCIETY
• Continue to extend our ethical, quality 
and corporate citizenship standards to our 
external suppliers.
• Expand our transparency initiatives in 
multiple domains while maintaining the 
beneﬁ ts of our decentralized business model.
• Maintain and enhance our citizenship 
and social responsibility activities despite 
challenging global economic conditions.
• Build on our foundation of strong 
partnerships and collaborations to develop 
and make available new treatments for 
diseases prevalent in the developing world.
• Continue to implement mechanisms to 
address contractor safety.
ENVIRONMENT
• Continue to achieve carbon dioxide 
reductions in our company-owned facilities 
as our business grows.
• Assess and manage potential risks of 
pharmaceuticals and personal care products 
to the environment.
BUSINESS
• Drive new growth from existing businesses 
and new ventures, and expand our global 
reach despite a diﬃ  cult worldwide economy.
• Reduce the risk to patients and consumers 
from growing counterfeit activity in many 
countries.
• Protect our intellectual property rights 
despite increasing challenges both in the 
marketplace and at a policy level.
• Overcome scientiﬁ c and regulatory 
challenges to sustain the productivity of 
research and development.
• Collaborate with others in countries 
around the world to drive meaningful health 
care reform that will enhance access and 
reward innovation.
S U C C E S S E S  &  C H A L L E N G E S
 1 For details, see www.jnj.com/connect/about-jnj/
views-positions/sales/.
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information is available, and
suﬃ cient time and resources
and unrestricted access to
management are provided in a
way that ensures the business
judgment of the Board is
exercised independently and in
the long-term interests of our
shareholders.
Additionally, our Policy on
Business Conduct sets expectations
for compliance with all laws
and regulations governing our
company’s behavior, including
in areas of employment,
environment, relationships
with health care practitioners,
ﬁ nancial reporting and political
contributions. This policy covers
all employees, and all senior
management members attest to
adherence annually (including
the chief executive oﬃ cer, chief
ﬁ nancial oﬃ cer and controller).
The Policy on Business
Conduct meets requirements of
the SEC rules promulgated under
Section 406 of the Sarbanes-
Oxley Act of 2002. In addition,
the Company has adopted a Code
of Business Conduct & Ethics for
Members of the Board of Directors
and Executive Oﬃ cers.1
STRUCTURE
William C. Weldon is
Chairman, Board of Directors,
and Chief Executive Oﬃ cer,
Johnson & Johnson. Our Board
of Directors meet a set of General
Criteria and are elected to the
Board by our shareholders each
year. We currently have 10 Board
members, nine of whom are
“independent” under the rules of
the New York Stock Exchange.
The Johnson & Johnson Board
of Directors holds the ultimate
authority of the Company, except
to the extent that shareholders
are granted certain powers under
the Company’s Certiﬁ cate of
Incorporation and By-Laws.
The Board appoints senior
management, who are responsible
for conducting business and
operations; provides oversight of
Citizenship
Overview
Caring for the world, one person at a time ... inspires
and unites the people of Johnson & Johnson.
We embrace research and science, bringing innovative
ideas, products and services to advance the health and
well-being of people around the world. Our 118,700
employees at more than 250 Johnson & Johnson
companies work with partners in health care to
touch the lives of over a billion people every day,
throughout the world.
We are guided in everything
we do by Our Credo, a
management document
authored more than 65 years
ago by Robert Wood Johnson,
chairman from 1932 to
1963, and by four strategic
principles: to be broadly based
in human health care; to follow
a decentralized management
approach; to manage for the
long term; and to focus on
people and values. These
principles drive us to ﬁ nd the
best possible solutions to
today’s most pressing health
care needs.
GOVERNANCE
Employees, oﬃ cers and
directors of Johnson & Johnson
are committed to the ethical
principles embodied in Our Credo
and to its supporting policies,
guidelines and standards.
Principles of Corporate
Governance, adopted in 2006,
apply to directors and senior
management, whose ethical
character, integrity and values are
the most important safeguard
of corporate  governance. These
principals lay out, among other
things, the processes in place for
the highest governance body to
make sure conﬂ icts of interest
are avoided, accurate and timely
management; and forms standing
Board Committees to assist in
fulﬁ lling its obligations.2
The Executive Committee
of Johnson & Johnson is the
principal management group
responsible for the operations
and allocation of Company
resources. In addition, certain
Executive Committee members
serve as Worldwide Chairmen of
Group Operating Committees,
which comprise managers who
represent key operations within
the Group, as well as management
expertise in other specialized
functions. These committees
oversee and coordinate the
activities of the Consumer,
Pharmaceuticals and Medical
Devices and Diagnostics business
segments. Each subsidiary within
the business segments is, with
some exceptions, managed by
citizens of the country where it is
located.
There are six standing
committees of the Board of
Directors: the Audit Committee,
the Compensation & Beneﬁ ts
Committee, the Nominating
& Corporate Governance
Committee, the Finance
Committee, the Public Policy
Advisory Committee, and the
Science & Technology Advisory
Committee.
The Public Policy Advisory
Committee (PPAC) is the primary
link to the Board of Directors
for reviewing and making
recommendations regarding
public policy issues facing the
company, public health issues, the
health and safety of employees
and the environment. The
PPAC comprises independent
Directors,  the Company General
Counsel and Vice Presidents for
Corporate Aﬀ airs, Government
Aﬀ airs & Policy and Worldwide
Operations.
Our governance structure
also includes Corporate Internal
Audit;  an independent auditor,
Pricewaterhouse Coopers, LLP;
WHO WE ARE
We are a family of
companies consisting of
more than 250 operating
companies in 57 countries.
We sell products
throughout the world
and had $63.7 billion in
worldwide sales in 2008
($32.3 billion from U.S.
companies and $31.4 billion
from international
companies).
Our sales are in three
business segments:
consumer, pharmaceutical,
and medical devices
& diagnostics.
Our investments in
research and development
were $7.6 billion in 2008.
We have been listed
on the New York Stock
Exchange since 1944
under the symbol JNJ.
Our worldwide
headquarters are in
New Brunswick,
New Jersey, USA.
2 For a complete list of our Board of
Directors, see www.investor.jnj.com/
governance/committee.cfm.
1 For more information, see www.investor.
jnj.com/governance/policies.cfm.
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5the Audit Committee of our
Board of Directors; and regular
review of business results by our
Executive Committee.3
WHAT WE DO
The operating companies of
Johnson & Johnson are organized
into three business segments:
Consumer, Pharmaceuticals and
Medical Devices and Diagnostics.
More information about
our products, and products by
company, is available on jnj.com
under Our Products. A listing of
subsidiaries as of December 2008
can be found in our 10-K Annual
Report, available on our website.4
CONSUMER
Products from our Consumer
companies stand at the ready to
improve the quality of everyday
life. We oﬀ er products for to treat these and many other
conditions.
MEDICAL DEVICES &
DIAGNOSTICS
Our Medical Devices &
Diagnostics businesses provide
doctors, nurses and hospitals with
the medical technologies they
need to restore the joys of life to
people who suﬀ er from some of
the world’s most pervasive and
chronic conditions.
STAKEHOLDER
ENGAGEMENT
Johnson & Johnson engages with
a broad range of external and
internal stakeholders on health,
health care, business, economic,
workplace, policy, social and
environmental issues. We try
to reﬂ ect the guidance and
wisdom of these diverse groups
as appropriate in our actions
and our policies. In 2009, we will
increase our eﬀ orts to gather
information and engage with
many of our stakeholders.
COMMUNITY
As health care continues to be
a focus of policy discussions in
the U.S. and around the world,
many stakeholders have asked
Johnson & Johnson to share
C I T I Z E N S H I P O V E R V I E W
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The ﬁ ve-year compound annual growth rates for worldwide, U.S. and international sales
were 8.8%, 5.0% and 13.6%, respectively. The 10-year compound annual growth rates for
worldwide, U.S. and international sales were 10.3%, 9.6% and 11.2%, respectively.
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All international geographic regions experienced sales growth during 2008, consisting of
7.3% in Europe, 10.5% in the Western Hemisphere (excluding the U.S.) and 13.9% in the
Asia-Paciﬁ c, Africa regions. These increases include the impact of currency ﬂ uctuations
between the U.S. dollar and foreign currencies, which had positive impacts of 5.5% in
Europe, 2.8% in the Western Hemisphere (excluding the U.S.) and 5.5% in the Asia-Paciﬁ c,
Africa region. In 2008, 2007 and 2006, the Company did not have a customer
that represented 10% or more of total consolidated revenues.
and information about baby
care, skin and hair care, oral care,
nutritionals, pain relief, topical
care and much more. Creating
meaningful innovation in health
care within the Consumer
business franchise relies on
a research strategy equally
rooted in technology and
consumer insights, in keeping
with our vision: Bringing Science
to the Art of Healthy Living.
PHARMACEUTICALS
Our Pharmaceutical com-
panies develop prescription
medicines that treat many of
the world’s most serious and
prevalent medical conditions.
These include Alzheimer’s,
anemia, autoimmune disorders
(such as rheumatoid arthritis
and psoriasis), cancer,
cardiovascular disease,
schizophrenia, epilepsy,
infectious disease, migraine
and pain. In 2008, we invested
$5.0 billion in pharmaceutical
research for new medicines
our perspective on what it
takes to achieve eﬀ ective and
compassionate health care for
all people. In early 2008, we
developed a short document
called The Promise of Health
Care. In doing so, we talked with
patient and physician groups,
public and private payers,
hospitals and academic centers,
nongovernmental organizations
(NGOs), government oﬃ cials,
academics, socially responsible
institutional investors and others.
We continue to solicit
feed-back from these and other
groups on this and many other
topics. For example, in developing
our access program for our
HIV medicines, we conducted
extensive outreach with dozens of
organizations and leaders in the
HIV and global health ﬁ elds.
Their thoughts help us continue
to grow and evolve both our
access and philanthropy
programs in global health.
Our Corporate Contributions
group also periodically
consults with NGO partners
and key stakeholders in social
responsibility to ensure that our
programs and collaborations are
eﬀ ective and relevant.
In another example, our
Healthy Planet 2010 goals
E M P L OY E E S  A S  C U S T O M E R S Our employees are among the
mothers, fathers and others who use our products. Arti Kalyanpur
is at the register while Brian Meltzer looks around the company
store at Johnson & Johnson world headquarters in New Brunswick,
New Jersey.
4 See www.investor.jnj.com/
governance/sec-ﬁ lings.cfm.
3 For more information on our
Corporate Governance, see www.
investor.jnj.com/governance.
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were informed by and set only 
after extensive dialogue with 
representatives from NGOs, 
industry, socially responsible 
institutional investors, academia 
and governments in the United 
States and Europe.  
CUSTOMERS
Customer feedback is a 
critical part of any successful 
business, and no more so than 
in the consumer and health care 
industries. Health is the most 
personal of issues, and as a health 
care company, we have an abiding 
obligation to listen to those who 
use or prescribe our products. 
Our operating companies use 
market research, customer 
contact centers, marketing 
partners and many other means 
to dialogue with customers. In 
addition, increasing numbers 
of our businesses engage in or 
support social networking 
related to health and 
wellness topics. This includes 
BABYCENTER® 5, Children 
with Diabetes 6, Diabetes Juvenil7, 
the VISTAKON® ACUMINDER™ 
and the “ADHD Moms” 
group on Facebook®. 
 At the corporate level, 
Johnson & Johnson launched 
the Kilmer House blog in 2006 
responding. Each operating 
company receives individual 
results and develops an action 
plan to address them. 
 On an ongoing basis, 
employees of the 
Johnson & Johnson Family of 
Companies can call an Employee 
Hotline or log on to an Employee 
Hotline Website operated by 
Global Compliance Services, 
Inc. to report concerns. Details 
are collected conﬁ dentially, 
and a summary report is sent to 
Johnson & Johnson Corporate 
Internal Audit. Reports are 
forwarded to the appropriate 
company or corporate staﬀ  for 
investigation and resolution.  
 
SHAREHOLDERS
We welcome the perspectives of 
our shareholders on a broad range 
of issues both formally, through 
the shareholder proposal process, 
and informally throughout the 
year. We meet with shareholder 
groups on matters of interest and 
make every eﬀ ort to respond to 
letters and other inquiries from 
shareholders. Shareholders may 
oﬀ er proposals by submitting 
them to the Company by 
and the blog JNJ BTW (By The 
Way) in 2007.  More internal 
contributors were brought to 
BTW in 2008 to increase its 
breadth of topics.
EMPLOYEES 
One of the most important 
opportunities to hear from our 
employees is the biannual Credo 
survey. The most recent one was 
completed in 2007, with more 
than 90 percent of employees 
the announced deadline.  
Proposals and other items of 
business should be directed to 
the Secretary at the principal 
oﬃ  ce of the Company, One 
Johnson & Johnson Plaza, New 
Brunswick, New Jersey 08933. 
TRANSPARENT & ETHICAL 
BEHAVIOR
Johnson & Johnson is known 
the world over for innovative, 
life-saving medical products 
and for the values we embrace in 
making these products available 
to serve patient needs. Our Credo 
communicates our commitment 
to putting patients ﬁ rst. Our Policy 
on Business Conduct and Health 
Care Compliance Guidelines require 
that employees conduct company 
business with the highest ethical 
standards.8 
 Our Health Care Compliance 
Guidelines, like the laws and 
industry codes they reﬂ ect, are 
intended to serve patients by 
safeguarding medical decision-
making from both the appearance 
and the fact of undue and 
improper ﬁ nancial inﬂ uence. In 
addition, we have numerous other 
policies aimed at ensuring the 
ethical behavior of our businesses. 
See our website for more 
information.9 
 We know that transparency is 
growing in importance to many 
of our stakeholders, and we are 
committed to providing open and 
accurate information. As part of 
our environmental goals, each 
facility provides information on 
its environmental program via 
a link on our website. Our U.S. 
pharmaceuticals, medical devices 
and diagnostics companies also 
register our clinical trials and 
provide results of adequately 
designed and well-controlled 
studies, regardless of their 
outcome, online. 
 Information on our support 
for professional medical 
C O M M U N I T Y  A N D  W O R K  Matthew Johnson is one of many 
employees who ﬁ nd ways to use the skills they draw on at 
work to serve their community. Johnson is a mentor to junior 
colleagues as well as local college students. As an active member 
of a Johnson & Johnson-sponsored aﬃ  nity group, he also regularly 
volunteers in his community. 
W O R K I N G  S A F E LY  Special equipment such as this Isolator helps 
employees like associate scientist Mary Kate Burd stay safe when 
working with chemicals.
5 babycenter.com
6 childrenwithdiabetes.com
7 diabetesjuvenil.com
8 These documents are available on our 
website at www.jnj.com/connect/about-
jnj/views-positions/sales/.
9 www.jnj.com/connect/about-jnj/views-
positions/business-practices/
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7education and charitable 
contributions made by our 
pharmaceutical, medical devices 
and diagnostics operating 
companies is also available online. 
 Johnson & Johnson is also a 
supporter of the U.S. Physician 
Payment Sunshine Act, which 
would require disclosure of 
payments made to physicians 
by companies. (See page 10  for 
details.)
PUBLIC POLICY 
Johnson & Johnson engages 
on a broad range of public 
policy issues, including policies 
aﬀ ecting health care, business, the 
economy and the environment. 
 In the U.S., we have advocated 
for passage of the State Children’s 
Health Insurance Program,  
and we support a strong 
and healthy Food and Drug 
Administration; enhancing 
health care access for the 
uninsured; preserving and 
creating jobs and enhancing 
infrastructure under the U.S. 
stimulus bill; and disclosing 
funding to physicians. We 
also support issues including 
patent reform, liability reform, 
health care reform, incentives 
for programs in wellness and 
prevention, a pathway to 
license biosimilar medicines, 
and enhanced comparative 
eﬀ ectiveness research. Around 
supported climate change 
legislation to reduce 
greenhouse gases and 
regulatory approaches to green 
chemistry product stewardship. 
  Johnson & Johnson also 
works in collaboration with 
many coalitions and partnerships 
to advance good public policy. 
A few of the groups in which 
we participate include the 
Healthcare Leadership Council, 
the Rand Compare project, the 
CEO Cancer Gold Standard™, 
the Partnership to Fight Chronic 
Disease, The Better Way, The 
21st Century Coalition for 
Patent Reform, The Climate 
Group, the World Resources 
Institute, the World Wildlife 
Fund’s Climate Savers program, 
the Carbon Disclosure Project 
and the U.S. Climate Action 
Partnership. In the European 
Union, Johnson & Johnson 
works with the European 
Justice Forum, the European 
Policy Centre, the Centre 
for Health Ethics in Society  
and the European Health 
Leadership Programme at the 
INSEAD Business School in 
Fontainebleau, France, and 
CSR Europe. 
 Johnson & Johnson also 
the world we consistently lobby 
for enhancements to health care 
systems that align with our policy 
positions, as outlined in The 
Promise of Health Care. 
 In the European Union, 
Johnson & Johnson has 
registered with the European 
Commission’s European 
Transparency Initiative to 
establish a code of conduct for 
lobbying with EU institutions. 
We also monitor and engage 
on a range of emerging 
scientiﬁ c issues and have 
issues letters of support on 
important policy issues before 
governments. For example, we 
sent letters to U.S. Congressmen 
to recommend a tax credit for 
renewable energy; to Senate 
leaders to support disclosure of 
payments that companies make 
to physicians; and to leaders 
of other countries supporting 
greenhouse-gas reductions. 
We were also a signatory to the 
“Bali Communiqué,” supporting 
action on climate change. 
 Other organizations with 
which we are aﬃ  liated through 
memberships, partnerships 
or sponsorships include the 
World Wildlife Fund, The U.S. 
Climate Action Partnership, 
The Conservation Fund, The 
Trust for Public Land, Wilderness 
Society, SafeKids Worldwide®, 
TogetherRx and the Partnership 
for Prescription Assistance.
POLITICAL CONTRIBUTIONS
In the U.S., contributions of 
approximately $1,108,000 were 
made to political parties and 
related institutions in 2008.10 
S H A R E D  VA L U E S  At Johnson & Johnson locations around the 
world, employees like Robert Foster in Ireland experience a similar 
culture—one that’s driven by shared values as stated in Our Credo. 
F R E S H  A I R  A N D  F R E S H  P E R S P E C T I V E S  Colleagues like Ai Ling Han, Phil Crowley and Steve Santos 
(from left) walk and talk on campus.
C I T I Z E N S H I P  O V E R V I E W
10 A list of all U.S. political contributions, 
updated annually, is available at 
www.investor.jnj.com/governance/
contributions.cfm. 
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The Promise 
of Health Care
  Start with this simple idea: Good health 
care can make a signiﬁ cant positive diﬀ erence 
in people’s lives. But what does it take to 
deliver good care to all? We consulted with 
patient groups, physicians, our employees, 
policymakers and others in health care, 
reﬂ ecting the guidance and wisdom of 
these diverse groups as we set forth our views 
in a short document called The Promise of 
Health Care.1
 “We created The Promise of Health Care 
to express our beliefs about what is needed 
to improve health care,” says Cliﬀ  Holland, 
Corporate Vice President, Government Aﬀ airs 
& Policy, Johnson & Johnson. “We believe 
the best systems are centered on the needs 
of individuals, oﬀ er access to health care 
coverage for all, and provide support to help 
people remain healthy, get early diagnosis and 
receive quality care when needed.”
 Importantly, The Promise of Health Care 
lays out the role of Johnson & Johnson in 
advancing good health care through our own 
actions and by working with others.
MEDICAL PROGRESS
Making the beneﬁ ts of medical progress 
available to more people helps to improve 
and save lives. Better outcomes for 
patients often depend on new or improved 
treatments. Research advances have led 
to more accurate diagnoses, less invasive 
treatments, faster returns to work, shorter 
hospital stays, fewer medical errors, more 
convenient treatments, fewer side eﬀ ects 
and longer lives.
 Continuing investments in R&D are 
essential if we want tomorrow’s care to 
be even better. Because research is risky, 
expensive and takes many years, it’s critical 
that companies conducting medical research 
operate in an environment that appreciates 
and rewards the investments they make.
 Robust intellectual property (IP) laws 
protect future medical advancement. In 
health care, IP protection—in the form of 
patents—guarantees the owner a set period 
of time to recoup research and development 
costs and realize a proﬁ t. In return, the 
owners have an obligation to make 
information about the patented product 
available to the public. Other researchers 
can then access this information to pursue 
new research and eventually create even 
more advances. 
 Many developing countries face 
public health crises. For example, malaria, 
tuberculosis and HIV/AIDS are devastating 
pandemics with enormous impacts around 
the world. Solving these important issues 
requires the engagement of many parts of 
society. It is important that laws protect 
intellectual property and data, but it is also 
important that these necessary protections 
not get in the way of providing access to 
people who are unable to pay for care. 
We believe that intellectual property 
should not be a barrier to access and that 
the best solution is for companies to 
work with local governments to develop 
diﬀ erential pricing approaches that protect 
IP as a driver of innovation while helping all 
countries meet their populations’ increasing 
demand for health care. (See related story 
on page 30.) 
  Medical progress depends on 
appropriate ways to evaluate the eﬀ ective-
ness of new treatments and adequate and 
fair reimbursement. Evidence-based 
medicine (EBM) is a growing trend in health 
care. In EBM, experts compare the available 
clinical evidence for various treatments 
that may be used in a particular disease, 
determine the best standard of care based on 
the comparison, and apply that standard to 
the care of patients. EBM aims to help health 
care providers decide who should get which 
treatment and under what circumstances.2 
 Transparent and eﬃ  cient regulatory 
and approval processes are also critical 
to medical progress, and strong and well-
respected regulatory authorities are a 
feature of eﬀ ective health care systems. 
Regulatory bodies look at the scientiﬁ c 
evidence a company develops about a 
product, weigh the beneﬁ ts of the product 
against its risks, and decide whether 
that product can be made available for 
use or prescribed for patients. We believe 
that strong, well-funded, eﬀ ective, 
scientiﬁ cally advanced, consistent and 
transparent regulatory review systems 
are essential to protect public health and 
build conﬁ dence in medical products. We 
support strengthening regulatory agencies 
so that they have the expertise, resources 
and tools to eﬀ ectively evaluate new 
scientiﬁ c advances.
HELP TO SHAPE EFFECTIVE 
HEALTH CARE SYSTEMS
We recognize that all members of the 
health care community must collaborate to 
advance good health. In addition to using 
our broad scientiﬁ c knowledge to develop 
new medical advances, we have an important 
responsibility to identify sustainable ways to 
help improve health care. The scope of our 
S O C I E T Y
Better health care for all is a challenge facing societies around the world. 
Our stakeholders have asked us about the role Johnson & Johnson can play
in advancing better health care for all. We look beyond our businesses for 
opportunities to encourage medical progress, advocate for eﬀ ective health 
care systems, and act to improve access to health care and health care products.
We have an important 
responsibility to identify 
sustainable ways to 
help improve health care.
1 Available at www.jnj.com/connect/about-jnj/views-
positioins/healthcare-systems.
2 For our view on how EBM should be applied, see 
www.jnj.com/connect/about-jnj/ views-positioins/
medical-progress.
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9actions around the world is wide:  It includes 
supporting health care reforms that put 
the individual at the center; helping others 
develop eﬀ ective prevention programs based 
on our own experience in employee health; 
and  developing educational programs that 
help build capacity and enable health care 
practitioners and government health and 
hospital administrators to upgrade their skills. 
We join in coalitions or other engagements 
with governments and policymakers to 
advocate for policies that will bring better 
health care to all.
ADVANCE GOOD HEALTH 
THROUGH OUR ACTIONS
We also focus on enhancing access to health 
care and health care products so that people 
across all economic and social circumstances 
have access to the treatments they need. 
We do this in many ways:
• We have a global access program for 
our HIV/AIDS medication, and we 
provide medicines and other products 
to people around the world through our 
product-giving and disaster-relief programs. 
(See page 30 for details.) 
• Our companies operate major patient-
assistance programs that provide donated 
medicine, discounts and other support 
to patients in the United States and 
Puerto Rico. (See page 3 for details.)
• We support public policy eﬀ orts to 
enhance basic health service coverage for 
limited-income and uninsured people, such 
as the State Children’s Health Insurance 
Program in the United States. 
• We also work closely with governments, 
health leaders, local and global 
nongovernmental organizations, and 
others throughout the world to help 
people access the health care products 
they need.
 Once a person is ill, access to care is 
paramount, but for those who are well, 
the key to continued health is prevention. 
From helping employees lead healthier 
lifestyles through our Health & Wellness 
programs to reducing preventable 
childhood injuries through the Safe Kids 
Worldwide® initiative, our programs help 
people get and stay healthy. We also provide 
broad health, disease and prevention 
information so people can understand and 
communicate with their doctors and 
play an active role in better managing 
their health.
A  P R O M I S E  F R O M  L I F E ’ S  F I R S T  B R E AT H  Through our businesses, the products we discover and our global philanthropy, we touch the 
lives of millions of people daily and help health care systems around the world deliver the promise of health care. One example, the Neonatal 
Resuscitation Program, is a powerful partnership between the Chinese Ministry of Health and the Johnson & Johnson Pediatric Institute, 
LLC that trains nurses to save the lives of babies who fail to breathe on their own at birth. Read more at jnj.com/ourstories.
T H E  P R O M I S E  O F  H E A L T H  C A R E
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In the Interest
of Our Patients
 Responsible, ethical behavior applied 
throughout the health care industry is 
essential to ensure the best interests of 
patients. Since 1943, when General Robert 
Wood Johnson wrote the ﬁ rst words of Our 
Credo, Johnson & Johnson employees have 
had a clear directive: to always put the needs 
of our customers ﬁ rst. 
 “Our Credo presents for us the idea 
that doing what’s right for customers, 
employees and communities leads to 
what’s right for stockholders,” says Russ 
Deyo, Vice President, General Counsel, 
Johnson & Johnson. “This sense of shared 
values is an important part of how we do 
business in a responsible, ethical way.”
 People who work at Johnson & Johnson 
and our operating companies must act 
according to the laws of the countries 
where we do business and comply with 
applicable industry codes of behavior. 
Beyond that, guidance comes from Our 
Credo, our Policy on Business Conduct and 
our many cross-organizational compliance 
standards and policies, as well as operating 
company policies that may relate to speciﬁ c 
matters relevant to individual companies. 
Johnson & Johnson recognizes that societal 
norms and expectations evolve, and we 
are continually reviewing our policies 
with an eye toward evolving standards and 
stakeholder feedback.
 Focusing on health care compliance, 
our guidances govern how we develop, 
manufacture, seek approval for, sell and 
market our health care products around the 
world. We formed a Corporate Compliance 
Committee in 2007 to provide an additional 
level of oversight for all health care 
compliance activities and to build on the 
experience of our ﬁ nancial, environmental 
and regulatory compliance eﬀ orts. Issues 
are discussed and, if necessary, raised to the 
Board of Directors and its Audit Committee 
and Public Policy Advisory Committee. 
RESEARCH & DEVELOPMENT
Johnson & Johnson companies conduct 
clinical trials in more than 40 countries 
to allow for wide representation of ethnic 
and cultural diversity. Our operating 
companies are required to follow the 
Declaration of Helsinki and the Belmont 
Report, which set clear guidelines for 
the ethical treatment of patients across 
borders. In addition, we are guided by Our 
Ethical Code for the Conduct of Research and 
Development.1 Clinical trials performed 
by our pharmaceuticals, medical devices 
and diagnostics, and consumer medicines 
businesses must adhere to all relevant 
statutes as well as our policies for registering 
and reporting company-sponsored clinical 
studies. 
 Our operating companies also take 
steps to ensure that the medical community 
has access to the best information about 
our products. We provide the results of 
adequately designed and well-controlled 
clinical studies, regardless of their outcome, 
in professional journals or on websites, 
including www.clinicaltrials.gov. Our 
clinical trial disclosure policies also reﬂ ect 
the requirements of the Food and Drug 
Administration Amendments Act of 2007 
(FDAAA or U.S. Public Law 110-85), 
which requires mandatory registration and 
results reporting for certain trials of drugs, 
biologics and devices.
 
PROFESSIONAL EDUCATION
We recognize the ethical responsibility and 
need to support health care professionals 
in their pursuit of the most current 
education so they can provide the best 
patient care possible. In the U.S., doctors 
are required to continue their medical 
education throughout their practicing 
lives. Medical specialty societies, academic 
institutions and other groups that provide 
medical education often look to health 
care companies to support their education 
programs. We believe this is an important 
way to advance medicine and health care, 
and our companies are expected to follow a 
set process when making educational grants. 
 Our Continuing Medical Education 
(CME) grants follow applicable codes and 
regulations. In the U.S., our pharmaceuticals 
and medical devices and diagnostics 
companies adhere to requirements of the 
S O C I E T Y
At Johnson & Johnson, we believe that health care is an extraordinary 
personal business that calls for responsible, ethical behavior. We put the 
needs of our patients ﬁ rst as we act according to our  policies, the laws of the 
countries where we do business and applicable industry codes of behavior.
Johnson & Johnson 
recognizes that societal 
norms and expectations 
evolve, and we are 
continually reviewing our 
policies with an eye toward 
evolving standards and 
stakeholder feedback.
1 This code and our other policies and positions 
related to conducting clinical trials can be found at 
www.jnj.com/connect/about-jnj/views-positions/
new-products/. 
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U.S. Food and Drug Administration, the
Accreditation Council for Continuing Medical
Education, the American Medical Association,
Pharmaceutical Research and Manufacturers
of America (PhRMA), AdvaMed and other
applicable industry standards. In 2009, we
placed additional restrictions on CME
grant-making. Also, we require our global
companies to follow relevant codes and
regulations for physician education, as well as
guidelines governing the education of other
types of health care professionals.
We also believe that disclosure of
professional educational grants helps
the public better understand the nature
and volume of supported programs. Our
U.S. pharmaceuticals, medical devices
and diagnostics companies provide this
information on their websites and update
it quarterly. They also provide a listing of
charitable contributions online.2
SALES & MARKETING
Communicating appropriately with health
care professionals is essential to our ability
to help improve and save lives. That’s why
we take many steps to ensure that we are
communicating accurately, truthfully and on
label at all times.
Our policies for responsible selling,
marketing and interacting with health
professionals are based on three principles:
Medical decision-making must be kept free
of improper company inﬂ uence; regulated
products must be promoted lawfully; and, in
the United States, pricing information must
be disclosed accurately to assure appropriate
reimbursement.
Each Johnson & Johnson operating
company around the world is required
to have an eﬀ ective compliance program
in place that includes written policies
and procedures for complying with
standards; a designated compliance oﬃ cer
and committee; eﬀ ective training and
education for employees; eﬀ ective lines
of communication; internal monitoring
and auditing procedures; enforcement of
standards through disciplinary guidelines;
a prompt response to detected problems
and procedures for carrying out corrective
action.
In addition, we follow the voluntary
AdvaMed Code of Ethics on Interactions
with Health Care Professionals and
the PhRMA Code on Interactions with
Healthcare Professionals, including updates
that took eﬀ ect in January 2009.
RELATIONSHIPS WITH PHYSICIANS
We are proud of the advances that result
from collaborations between physicians
and our operating companies. Yet we
believe it is important that all participants in
health care guard against potential conﬂ icts
of interest. Thoughtful policies, strong
compliance safeguards and disclosure all
help. Johnson & Johnson has been a strong
and early supporter of greater transparency
regarding payments made to physicians.
The company supports the Physician
Payment Sunshine Act and is working
with Congress on a revised version of
that bill. Our U.S. pharmaceuticals and
medical devices and diagnostics businesses
have also committed to voluntarily disclose
payments to physicians by June 2011.3
PATIENT & CONSUMER
EDUCATION
Today, people want to be active
participants in their health care and that
of their families. We believe it’s important
to help people understand how to
prevent illness, navigate the health care
system and get the best care they can if
they get sick. Our companies use many
forms of communication, including
educational brochures, websites and
videos, as well as direct-to-consumer (DTC)
advertising on television and in magazines
that gives people information they can
use when communicating with their
doctors about the beneﬁ ts and risks of
treatments.
Johnson & Johnson and its operating
companies have established guidelines that
apply to all forms of DTC communication,
and we regulate such communication by our
pharmaceuticals and medical devices and
diagnostics businesses.4
We also believe that providing
information to patients in a way that
enhances their health literacy is important,
and we are developing training for our
companies to further these eﬀ orts.
D I S C O V E R I N G  A N D  D E V E L O P I N G  P R O D U C T S Vuyokazi Sidelo and our other
scientists and professionals put the needs of our patients ﬁ rst. They work responsibly
and ethically, driven by the idea that “the patients are waiting.”
2 More detailed information and supporting policy
statements about responsible professional education
are available on our website at www.jnj.com/wps/
wcm/connect/735c0e804af97de9b753bf10588a2
d62/educational-programs-and-material-support.
pdf?MOD=AJPERES.
4 These principles and our processes for ensuring
accountability to them are provided on our website
at www.jnj.com/connect/about-jnj/views-positions/
sales/.
3 For more on our transparency initiatives, see www.
jnj.com/connect/about-jnj/views-positions/sales/.
I N T H E I N T E R E S T O F O U R P A T I E N T S
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S O C I E T Y
Social
Performance
MANAGEMENT OVERVIEW  
Our social performance is 
guided by Our Credo as well as 
numerous social policies and the 
systems and procedures 
that implement them, both 
within our company and 
beyond. The following pages 
provide a sampling of our 
policies, goals and performance, 
and the mechanisms we use to 
manage the social aspects of 
our business. While there 
are many ways to consider 
these issues, we have divided 
these topics into three 
broad categories: Social 
Obligations to Our Patients 
and Customers, Social 
Obligations to Our Employees, 
and Social Obligations to Our 
Communities.1 In addition 
to the topics discussed on 
pages 8 through 11, here are 
other aspects of our social 
performance in 2008.
OUR PATIENTS & 
CUSTOMERS 
DISCOVERING AND 
DEVELOPING PRODUCTS
From theory to therapy, 
discovery to commercialization, 
our research and development 
teams adhere to the highest 
ethical standards in the 
work that’s conducted in our 
laboratories, as well as in our 
clinical research with people. We 
seek to operate our businesses in 
alignment with societal norms 
and in accordance with accepted 
international standards for 
scientiﬁ c work (see “In the 
Interest of  Our Patients,” 
page 10). In recent years, 
interest in the scientiﬁ c and 
laboratory activities of health 
care companies, particularly as 
they relate to the use of animals 
and stem cells in medical 
research, has increased, and we 
understand and respect those 
interests. 
ANIMAL WELFARE
In 2008, we began updating our 
Policy on the Humane Care and Use 
of Laboratory Research Animals to 
include additional regulations 
and guidance regarding animal 
welfare. It is the policy of the 
Johnson & Johnson Family 
of Companies to use animals 
in laboratory research to the 
minimum extent necessary to 
assess the safety and eﬃ  cacy 
of our products for use 
in humans and animals. 
Although in vitro systems have 
contributed to reducing animal 
use, they cannot currently 
obviate the need for animal 
studies. 
 Nonetheless, 
Johnson & Johnson companies 
are committed to the three 
“R” principles—replacement, 
reduction and reﬁ nement—as 
they apply to animal testing. We 
do not conduct animal testing 
on our personal care products, 
nor do we ask others to test 
on our behalf, except when 
required by law or regulation. 
We comply globally with 
requirements of the EU ban on 
animal testing for cosmetics.2
STEM CELLS
Human stem cells are immature 
cells with the potential to give 
rise in the laboratory to virtually 
any cell type. As a research tool, 
stem cells promise to expand 
understanding of diseases as 
well as normal body processes.
 In recognition of the potential 
importance of human stem 
cells for medical advances, 
our Committee on Human 
Stem Cell Research has 
established guidelines to 
govern consideration of the 
use of stem cells in research 
funded or conducted by 
Johnson & Johnson and its 
aﬃ  liated companies. 2
INGREDIENT SAFETY
Our companies buy and 
manufacture an array of raw 
materials, active ingredients, 
packaging components and 
other supplies to make our 
ﬁ nished products. The safety 
and quality of these materials 
is critical to the success of the 
ﬁ nal products and to protecting 
customers. Our companies 
conduct quality evaluations 
before using raw materials, and 
we hold our suppliers to our 
high standards of material safety 
and quality.3
PRODUCT SAFETY 
Every product we sell must  
meet our high standards of 
quality, safety and eﬃ  cacy, and 
our products are assessed for 
health and safety improvements 
at each major stage of their 
lifecycle. Our professionals 
from a variety of scientiﬁ c 
backgrounds conduct 
assessments as part of detailed  
quality, safety and eﬀ ectiveness 
tests before any new product is 
introduced. 
 Further testing of ﬁ nished 
products is done to ensure 
products work as  intended. 
Our companies continue to 
assess their products after they 
reach the market to identify any 
safety issues. Procedures for 
immediate “ﬁ eld action” are 
in place to handle problems, 
if found. Additionally, our 
operating companies employ 
a variety of mechanisms to 
measure customer satisfaction, 
including surveys, website 
interactions, focus groups and 
patient advisory groups. 
GENETICALLY MODIFIED 
ORGANISMS
Concerns have been raised 
regarding the use of genetically 
modiﬁ ed organisms (GMO). 
This technology—the 
abiity to alter the genetic 
makeup of cells—has led 
to medical advances. Our 
biopharmaceutical companies 
work closely with regulatory 
authorities around the world 
to ensure that appropriate 
standards and controls are in 
place when these technologies 
are used. 
NANOTECHNOLOGY
Nanotechnology is a more 
recent development, 
involving very tiny materials. 
Some people have raised 
concerns about the safety 
of nanotechnology. 
Nanotechnology oﬀ ers the 
potential to develop improved 
medicines, medical devices and 
personal care products such 
as shampoos, body washes, 
sunscreens and cosmetics. We 
participate in nanotechnology 
scientiﬁ c forums, monitor 
regulatory developments, 
Our social 
performance is 
guided by Our Credo 
as well as numerous 
social policies 
and the systems 
and procedures that 
implement them, 
both within our 
company and 
beyond. 
1 For more information on our social 
policies, positions and programs, visit 
www.jnj.com. 
2 For more information, see www.jnj.
com/connect/about-jnj/views-positions/
new-products.
3 For more information, see www.jnj.
com/connect/about-jnj/views-
positions/product-safety.
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a minimum complies with local 
requirements. 
DIVERSITY & 
NONDISCRIMINATION 
Our Global Oﬃ  ce of Diversity 
and Inclusion works to attract, 
retain and develop a diverse 
workforce, guided by our 
Global Diversity and Inclusion 
Vision.6 In 2008 we established 
diversity councils to assist 
in more strategic alignment 
of our business sectors, and 
going forward our focus will 
be on strengthening internal 
communication around 
diversity. 
AFFINITY GROUPS
Initiated and driven by 
employees, aﬃ  nity groups 
around the Company provide 
an open forum for idea 
exchange and action, as well as 
an opportunity to strengthen 
linkages to and within our 
diverse communities. In 2008, 
nine aﬃ  nity groups were active 
within the Johnson & Johnson 
Family of Companies.7
ADVANCEMENT OF WOMEN 
Launched in 1995, the Women’s 
Leadership Initiative (WLI) 
grew out of a longstanding 
commitment to programs 
that increase the diversity 
of our workforce. The WLI 
seeks to align with, deﬁ ne and 
enhance the policies that will 
attract, develop and retain 
talented women. In 2008, 
support continued for our 
WLI-sponsored development 
programs, and we expanded and 
strengthened the WLI at the 
chapter level. 
BENEFITS 
Johnson & Johnson knows that 
beneﬁ ts are critical in attracting 
and retaining our workforce. 
Highly competitive beneﬁ ts are 
provided to full-time employees, 
as well as active salaried or 
S O C I A L  P E R F O R M A N C E
research the environmental 
impact of nano-sized particles, 
investigate product safety and 
develop advanced protective 
methods for working with nano-
sized materials.4
ANTI-COUNTERFEITING
Johnson & Johnson launched a 
Global Brand Protection group 
in 2007 and held our ﬁ rst Global 
Brand Protection Summit in 
2008 to examine the scope of 
criminal counterfeiting activity, 
its impact on business and how 
best to address these risks. 
 All prescription drug 
products have anti-counter-
feiting features, and this 
drives the eﬀ ort to continually 
evaluate new technologies 
and tools to protect patients 
who use Johnson & Johnson 
products. We also conduct 
training for those who handle 
and sell our products, to 
facilitate early identiﬁ cation of 
potential risks. 5
ACCESS TO OUR PRODUCTS
Access to health care is at 
the forefront of public policy 
discussions these days, and it is a 
topic about which we care deeply. 
(See “The Promise of Health 
Care” on page 8 and “Distributing 
Hope & Help” on page 30 for 
more information, or visit  
www.jnj.com.)
OUR EMPLOYEES, 
CONTRACTORS & 
PARTNERS  
Our workforce statistics, 
retention rates and salary 
information are currently 
tracked at the operating 
company level only. In 2009 
we are implementing a new 
data management system 
to allow us to capture this 
information in a concise way 
enterprise-wide. Regarding 
minimum notice periods 
for signiﬁ cant operational 
changes, Johnson & Johnson at 
non-union hourly regular or 
casual part-time employees 
who are regularly scheduled to 
work 19 or more hours per week 
each year, and active full-time 
temporary extended salaried or 
non-union hourly employees. 
Beneﬁ ts provided to union 
employees are negotiated per 
contract. 
 
PERFORMANCE MANAGEMENT 
Performance management 
is handled at the individual 
company or franchise level; 
data relating to performance 
management is not currently 
collected at the enterprise 
level. However, in 2009 we are 
implementing an upgrade to our 
data collection and management 
processes that will enable us to 
compile this information at the 
enterprise level going forward. 
TALENT MANAGEMENT 
& TRAINING
The skill and career 
advancement of our workforce 
is critical to the success of 
both our individual employees 
and Johnson & Johnson. We 
oﬀ er on-the-job training 
supplemented by extensive, 
globally accessible training 
and development resources. 
Oﬀ erings are provided at the 
individual, team, organizational 
and leadership levels and 
include leadership development 
and management education and 
development programs. 
 Our School of Personal 
and Professional Development 
and our eUniversity are 
available online to all employees 
and contain eLearning and 
classroom courses to support 
training and development needs. 
Individual career development 
goals, supported by a global 
career step curriculum, are 
set and tracked through our 
Global Learning Management 
System. External educational 
development is supported 
through our Educational 
Assistance program. 
 Training hours are provided, 
P R O D U C T  S A F E T Y  Employees like Nilesh Patel, with 
Johnson & Johnson Pharmaceutical Services in the United States, 
perform quality, safety and eﬀ ectiveness tests during research 
and development, one of the product lifecycle stages where 
product safety is assessed.
4  For more details on our positions 
related to GMO and nanotechnology, see 
www.jnj.com/connect/about-jnj/views-
positions/product-safety/.     
5  For further information, see Anti-
Counterfeiting Measures at www.jnj.
com/connect/about-jnj/views-positions/
product-safety/.
7 See www.jnj.com/connect/about-jnj/
diversity/programs.
6 See www.jnj.com/connect/ about-jnj/
diversity/programs.
76617_L1_r2.indd   13 5/22/09   12:21:46 AM
14 J O H N S O N  &  J O H N S O N  2 0 0 8  S U S T A I N A B I L I T Y  R E P O R T
S O C I E T Y
tracked and documented 
by the individual operating 
companies. Minimum training 
requirements are established 
according to the individual role, 
and an average of eight hours or 
more of training per employee is 
provided per year. 
CONTRACTOR MANAGEMENT
Our occupational safety 
program includes systems to 
protect contract workers at our 
facilities. Nonetheless, over the 
past two years, we experienced 
several contractor incidents 
that resulted in serious injury 
and one death in 2007.  As a 
result, we are giving heightened 
attention to contractor safety 
throughout our operations and 
Environmental Health Safety 
(EHS) organizations. In April, 
the Worldwide Operations 
Council responded to a 
signiﬁ cant rise in the number 
and severity of contractor- and 
machine-related injuries by 
calling for a worldwide Safety 
Time-Out!—a pause in our 
operations to reﬂ ect on where 
the next accident might occur 
and prevent it before it happens. 
 A key component of the 
Safety Time-Out! was employee 
engagement. Operations 
leadership used this opportunity 
to encourage dialogue on 
challenges that are impacting 
safety on the plant ﬂ oor, during 
construction and maintenance 
activities, and in our 
laboratories. In addition, our 
Contractor Management standard 
has been revised. It ensures 
that contractors are suﬃ  ciently 
qualiﬁ ed and competent to 
do the tasks they are hired to 
do, and that the qualiﬁ cations 
required for each job are clearly 
delineated. 
 We have also identiﬁ ed new 
contractor metrics that will 
be tracked going forward; the 
percentage of projects in which 
there was an assessment of 
EHS risks prior to contractor 
selection; and level of contractor 
engagement. This program was 
designed and piloted in 2008, 
and it is being fully deployed 
in 2009. 
EMPLOYEE HEALTH AND 
WELLNESS 
As the largest health care 
company in the world, 
Johnson & Johnson is dedicated 
to promoting the health of its 
employees and their families, 
and the communities in which 
they work. From the 1978 
inception of the LIVE FOR 
LIFE program to present-day 
eﬀ orts to create and sustain 
a global culture of health, 
Johnson & Johnson Global 
Health Services initiatives 
have been recognized as a key 
component of the Company’s 
social responsibility and 
sustainability. Our goal is to 
create a more productive, 
health-conscious workforce and 
reduce health-related costs. 
 Global Health Services 
works to improve and sustain 
employee health by providing 
Occupational Health services, 
Employee Assistance, and 
Wellness and Health Promotion 
programs that are customized 
according to location, culture 
and speciﬁ c health needs. 
To meet this objective, 
Johnson & Johnson established 
Healthy People 2012 goals; see 
our progress in the chart at left. 
 In 2008, as part of our health 
outreach eﬀ orts, our on-site 
occupational health clinics 
expanded their oﬀ erings. 
Under our wellness initiative, 
our health proﬁ le tool, which 
provides employees with an 
online health risk assessment, 
is now available in 11 languages, 
providing potential access to 
nearly 60 percent of employees. 
Other wellness programs 
include a Global Tobacco-Free 
Workplace Policy (implemented 
at 98 percent of our sites); the 
HIV/AIDS Policy (implemented 
at 100 percent of U.S. and 
Puerto Rico sites, and 83 percent 
globally); our EatComplete 
program, a healthy-eating 
initiative (available at 85 percent 
of eligible cafeterias at our U.S. 
locations); and the Million Step 
Challenge (with more than 
20,000 employees participating 
since 2005). Additionally, 
Johnson & Johnson has been 
accredited for three years as 
a member of the CEO Cancer 
Gold Standard™, developed to 
help organizations reduce the 
burden of cancer.8
 A high-risk analysis of U.S. 
employee health proﬁ le data 
revealed that the top three risks  
in our employee population are 
unhealthy eating, insuﬃ  cient 
physical activity and obesity. 
Since the late 1990s, we have 
seen risk factors declining. 
 Employee access to Employee 
Assistance Programs (EAP) has 
continued to expand across the 
globe. In 2008, EAP counselors 
delivered resilience skill-building 
training to 16,000 employees. 
Also in 2008, of the 100,000 
employees who had access to 
these services, more than 10,000 
utilized the expertise of mental 
health professionals for personal 
and work-related concerns and 
reported 98 percent satisfaction 
with the quality of care they 
received. 
WORKPLACE SAFETY
Johnson & Johnson has had 
global workplace safety 
standards for over 20 years. 
Safety is audited by independent 
teams, and performance is 
discussed with the Public Policy 
Advisory Committee of the 
Board of Directors.
 In 2007, Johnson & Johnson 
established Safe People 
2010 goals to reiterate our 
commitment to preventive 
programs that promote strong 
safety performance. This is 
measured by tracking injury and 
illness rates, such as Lost Work 
Day Case (LWDC) and Serious 
Illness and Injury Case (SIIC) 
HEALTHY PEOPLE 
2012 GOALS
YEAR-END 2008 RESULTS
 Create, promote and 
sustain an organizational 
culture of health
75 percent of sites/companies worldwide 
promote 13 health services offerings.
85 percent of sites/companies offer 
at least ﬁ ve health offerings; 88 percent of 
U.S. sites offer all 13.
Reduce population
health risk factors
More than 70 percent of employees who 
participated in the voluntary health screening 
were in the “low risk” health category.
85 percent of U.S. employees who 
participated in the voluntary health screening 
were in the “low risk” health category 
(outside the U.S. this was 63 percent).
Promote a consistent
approach to the
deployment of
occupational health
services and standards
More than 93 percent of periodic medical 
surveillance was completed on time.
Process deployed. All sites with planned 
periodic medical surveillance exams had 
completed more than 93 percent on time.
As the largest 
health care company 
in the world, 
Johnson & Johnson 
is dedicated to 
promoting the health 
of its employees and 
their families, and 
the communities in 
which they work.
8 For more information on these 
and other wellness programs, see 
www.jnj.com/connect/about-jnj/
views-positions/good-health.
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rates, which we aim to maintain 
at or below 2006 levels. 
 While our lost-workday case 
rate remains almost ﬁ ve-fold 
better than that of our peer 
benchmark group, our 2008
rate missed our goal for a few 
reasons. First, we changed 
our record-keeping guidelines 
to strengthen consistency in 
reporting across the globe. We 
now include all cases that are 
reported to the local government 
in several European countries, 
including injuries such as those 
associated with vehicle accidents 
that occur while commuting. 
Second, we have seen a rise in 
injuries associated with slips, 
trips and falls. Many of these are 
occurring in non-manufacturing 
settings such as during sales 
calls or while working in oﬃ  ce 
settings. Throughout 2009, we 
will improve safety awareness 
outside our manufacturing areas 
with a communication campaign 
speciﬁ c to oﬃ  ce locations.
COMPLIANCE
We have goals for zero safety 
violations and zero ﬁ nes. 
In 2008, we experienced 
14 safety noncompliances, all 
of them minor in nature. We also 
incurred a $600 ﬁ ne for a safety 
violation at our Cordis facility in 
Fremont, California.
ERGONOMICS
Ergonomic injuries accounted for 
20 percent of lost-workday cases 
in 2008, down from 33 percent in 
2007 (see chart at bottom right). 
We continue to implement an 
aggressive strategy to modify 
high-risk tasks. 
FLEET SAFETY
SAFE Fleet, our ﬂ eet-safety 
program, provides services to 
more than 36,000 employees 
worldwide. The company 
vehicle serves as a workplace 
S O C I A L  P E R F O R M A N C E
for the majority of these 
employees, some of whom 
spend as much as 60 percent of 
their time driving on company 
business. Our rate of accidents 
per million miles driven 
(APMM) has decreased by 37 
percent since 1995. 
 In 2008, the total number of 
accidents worldwide and the 
percent of vehicles in accidents 
stayed relatively ﬂ at compared 
to 2007. However, our APMM 
increased to 5.56, primarily due 
to an increase in accidents in 
North America (see chart at far 
right). While a benchmarking 
exercise conducted in 2008 
showed that Johnson & Johnson 
ranks lowest in APMM among 
pharmaceutical companies, 
we still experience more than 
4,000 vehicle accidents a year. 
In response, we are increasing 
our training eﬀ orts, and in the 
U.S., we are categorizing drivers 
according to their level of risk 
so we can focus our eﬀ orts on 
high-risk drivers.
OUR COMMUNITIES
VOLUNTEERISM
The Johnson & Johnson 
Volunteer Support Program 
(VSP) was created in 
1993 to support employee 
initiatives that embody the 
Johnson & Johnson Credo 
spirit. The VSP sponsors on-site 
volunteer opportunities, creates 
partnerships and relationships 
with local nonproﬁ t 
organizations, coordinates 
volunteer days and recognizes 
excellence in volunteerism. 
Currently available only in 
the U.S., this program is being 
expanded to include retirees 
and employees outside the 
United States. We estimate 
that 80 percent of our U.S. 
employees (more than 35,000
employees) are active volunteers 
in their communities. 
OUR GIVING
Johnson & Johnson and its 
operating companies work to 
make life-changing, long-term 
diﬀ erences in human health by 
targeting the world’s major 
health-related issues and 
supporting philanthropic eﬀ orts 
through community-based 
partnerships. The company’s 
eﬀ orts focus on saving and 
improving the lives of women 
and children, building health 
care capacity, preventing 
diseases and reducing stigma, 
and disaster relief. 
 Our approach is to partner 
with community-based organi-
zations around the world to ensure 
that our giving is geographically 
diverse and aligned with a strategic 
plan. For more information on the 
history of our giving, visit www.
kilmerhouse.com.
 Examples from 2008 include:
BUILDING HEALTH CARE 
CAPACITY
This philanthropy focuses 
on supporting activities that 
address the global health care 
worker shortage, provide 
skills-based training programs 
for health care workers, and 
oﬀ er health education and 
development opportunities for 
community members. 
 One example of our 2008
eﬀ orts: Johnson & Johnson 
supported the Management 
Development Institute, an 
intensive one-week training 
program that enhances the 
management skills of health 
care leaders in East and 
West African AIDS-service 
organizations devoted to the 
care, treatment and support of 
people and their families living 
with HIV/AIDS. More than 
ERGONOMIC INJURIES 2005 2006 2007 2008
% of Lost Workday Cases 21 28 33 20
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U N A M O S  A L  M U N D O  P O R  L A  V I D A  ( C A R I N G  F O R  V E N E Z U E L A’ S 
S T R E E T  C H I L D R E N )  Johnson & Johnson partners with this 
organization to educate some 3,500 children who live on the streets 
of Caracas each year.
INDICATOR 1995 2005 2006 2007 2008
J&J Lost Workday Case Rate 
Per 100 employees (Goal: <0.07) 0.31 0.06 0.07 0.08 0.10
Peer Pharmaceutical Companies 
Per 100 employees (average of 14 companies) 0.80 0.41 0.47 0.51 0.47
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240 leaders from 12 countries 
have graduated since 2006. 
 Another example is our 
eﬀ ort to increase health literacy 
among Head Start parents in 
the U.S. Now in its eighth year, 
the UCLA/Johnson & Johnson 
Health Care Institute was 
created to help educate and 
empower Head Start parents. 
This successful health literacy 
program has trained more 
than 10,000 parents in 35 
states—impacting nearly 20,000 
children—and is continuing 
to impact many families and 
communities.
SAVING & IMPROVING 
LIVES 
Our philanthropic eﬀ orts in 
this area address safe birthing 
and infant care, teaching 
life skills for young people, 
assisting women and children 
at risk for abuse and violence, 
disaster preparedness and 
relief, and providing economic 
empowerment. 
 One example of our 
2008 eﬀ orts: Following the 
devastating earthquake that 
struck Sichuan Province in 
China in May 2008, killing more 
than 80,000 people and injuring 
hundreds of thousands more, 
we provided needed supplies 
to the area. We also partnered 
in a post-quake Children’s 
Psychological Rehabilitation 
and Aid Program to train 
health workers on basic 
psychological intervention 
skills, an eﬀ ort that will result 
in the training of 600 workers 
and 3,000 volunteers in the next 
two years. 
 In Europe, we have 
partnered with the European 
Child Safety Alliance, the 
European Commission and the 
Consumer Safety Institute in 
the Netherlands for the past 
nine years to address child 
safety issues throughout the 
region. Campaigns focus on 
safety issues in the home, such 
more than 6,000 HIV-positive 
mothers-to-be. 
DISASTER RELIEF
Several major disasters 
devastated many lives 
throughout the world in 
2008. In keeping with Our 
Credo, and with help from 
our numerous partners, the 
Johnson & Johnson Family 
of Companies responded to 
17 disasters in more than 20 
locations. From civil unrest 
in Africa to ﬂ ooding in South 
America to earthquakes and 
cyclones in Asia to hurricanes 
in the Caribbean and the U.S., 
product and monetary support 
assisted thousands who were 
aﬀ ected. And following the 
earthquake in China’s Sichuan 
Province, Johnson & Johnson 
Chairman and CEO William 
C. Weldon co-led the U.S. 
government’s public-private 
partnership mission to 
China to explore long-term 
rebuilding eﬀ orts. 
OUR SUPPLY CHAIN
MANAGING OUR SUPPLIERS 
Johnson & Johnson utilizes 
a network of approximately 
7,100 direct material suppliers 
to produce some of our 
products. Our purchasing 
agreements with suppliers 
include numerous expectations. 
At a minimum, suppliers are 
required to comply with all 
applicable legal requirements 
related to business conduct, 
labor and employment 
practices, and our Policy on 
Employment of Young Persons. 
 We also expect 
suppliers manufacturing 
ﬁ nished products or active 
pharmaceutical ingredients for 
us to conform to a broad set of 
standards called our Standards 
for Responsible External 
Manufacturing. These further 
deﬁ ne our expectations for 
appropriate business conduct, 
labor and employment, and 
EHS practices. They were 
rolled out to over 800 external 
S O C I E T Y
as falls, burns and scalds. The 
partnership led to a European 
Union ban of all non-child-
resistant lighters.
PREVENTING DISEASES & 
REDUCING STIGMA
Here we focus our philanthropy 
on preventing HIV/AIDS; 
reducing the impact of 
disease among the poor and 
underserved through product 
donations and produce-to-
give programs; supporting 
hygiene and environmental 
stewardship; reducing the 
impacts of chronic disease 
and obesity; and supporting 
community interventions 
and family caregiving 
programs that reduce the 
institutionalization and 
abandonment of individuals 
living with chronic disease, 
mental illness or long-term-
care needs. 
 A 2008 highlight is our 
partnership in Mexico with 
Project HOPE and the local 
Neza Health District, where 
we promote healthy eating 
and exercise habits among 
children, and educate families 
and teachers on eﬀ ective ways 
to convey positive nutritional 
messages to children through 
the “Healthy Habits for a 
Healthy Weight” program. 
The program, started in 
2007, raises awareness of the 
connection between diabetes 
and obesity. 
 Also in 2008, we were 
honored by the Global Business 
Coalition for our philanthropic 
eﬀ orts and partnership with 
mothers2mothers (m2m). This 
partnership provides education 
for HIV-positive pregnant 
women in South Africa to 
prevent mother-to-child 
transmission of the disease 
and trains new HIV-positive 
mothers to mentor other HIV-
positive pregnant women. 
Since 2005, m2m has expanded 
to 15 sites. In 2008,  it served 
manufacturers in 2007, and 
since then we have audited 
35 percent of our external 
manufacturers against our 
Standards. Our longer-term 
Healthy Planet 2010 goal is for 
all external manufacturers to 
conform to these standards 
by 2010. 
 Assessing conformance 
against a broad set of standards 
is a challenging activity 
requiring signiﬁ cant resources 
and expertise, especially given 
the breadth of our supply 
base. Our participation in the 
Pharmaceutical Supply Chain 
Initiative (PSCI) is an eﬀ ort 
to gain some eﬃ  ciency within 
the industry and to drive, 
through collaboration, real 
improvements in the supply 
base, especially in Asia-Paciﬁ c 
and Eastern Europe. We have 
also undertaken our own eﬀ orts 
to build supplier capability in 
EHS, sharing training content 
and practices with our key 
suppliers. 
 In 2008, we began 
reaching out to our external 
manufacturers to ask them 
to measure and manage their 
carbon emissions and energy 
use by partnering with us in 
the Carbon Disclosure 
Project’s Supply Chain 
Leadership Collaboration. 
Although these eﬀ orts had 
limited success, it was a 
ﬁ rst step in our journey to 
emphasize the importance 
of energy conservation and 
reduced emissions. 
GREENING THE 
SUPPLY CHAIN
In 2008, we recruited six 
new suppliers (including 
three diverse suppliers) into 
the U.S. Environmental 
Protection Agency’s (EPA) 
Green Supplier Network, 
which educates suppliers on 
lean and clean manufacturing 
techniques. We also continued 
to integrate sustainable 
practices into core 
procurement processes as 
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well as our supply chain.
 For example, our Consumer 
segment has developed a 
proprietary screening process to 
more accurately score ingredients 
and products for environmental 
impacts. This innovative tool
 allows our formulators to 
compare ingredients for
downstream environmental 
impact and provide suggestions 
for alternatives. To date, we 
have scored 70 percent of the 
chemicals used worldwide in the 
Consumer Group. 
 We also continue to evolve 
our supplier raw material 
questionnaire to include criteria 
that help us to assure that the 
also provided support in 
obtaining certiﬁ cation, such 
as that oﬀ ered through the 
National Minority Supplier 
Development Council, via 
free consulting services and 
training. 
 We also partner with 
groups such as the National 
Minority Manufacturing 
Institute to develop 
partnerships with minority- 
and women-owned businesses. 
Benchmarking eﬀ orts ensure 
that we continue to identify 
and use existing best 
management practices in the 
recruitment and development 
of these businesses. 
materials we use go beyond 
meeting safety and regulatory 
requirements to address key 
product stewardship attributes 
that we review. 
SUPPLIER DIVERSITY
As part of our commitment to 
our communities, we extend 
our inﬂ uence to encourage 
the values we hold internally. 
In 2008, Johnson & Johnson 
added over 100 new minority- 
and women-owned business 
suppliers, and increased our 
spending with these businesses 
by more than $80 million, an 
increase of 6 percent over 
2007.  Johnson & Johnson 
HUMAN RIGHTS 
Johnson & Johnson has a 
large international and global 
sourcing presence, and human 
rights are an issue we care about 
and will examine further in 
2009. We know that operations 
conducted in some parts of 
the world present a risk for 
incidents of child labor,  forced 
or compulsory labor, or other 
human rights abuses. To avoid 
these conditions, we have 
established Global Labor and 
Employee Guidelines and a Policy 
on Employment of Young Persons, 
which set out our expectations 
for employment at our 
own sites. 
 These expectations are 
also included in our Standards 
for Responsible External 
Manufacturing, mentioned 
on page 16. All external 
manufacturers are required 
to enter into an enforceable 
written agreement to comply 
with these policies and 
standards, submit to periodic 
inspections, and maintain 
the records necessary to 
demonstrate conformance. 
POLICY ENGAGEMENT
Johnson & Johnson takes 
seriously our obligations to 
the world community. This 
is evidenced by many of the 
public positions we take and 
by the issues on which we 
engage. Examples include 
expanded health care access 
and health care reform in the 
U.S. and other countries (see 
“The Promise of Health Care,” 
page 8); our support for strong 
regulatory bodies around 
the world; our participation 
in the U.S. Climate Action 
Partnership; our engagement 
in advancing wellness and 
prevention; our work on the 
CEO Cancer Gold Standard™; 
our expanding work on global 
health with many international 
bodies; and our work to 
enhance road safety with the 
United Nations Road Safety 
Collaboration (UNRSC). 
S U P P O R T I N G  T H O S E  A F F E C T E D  B Y  H I V/A I D S  Fuyang AIDS Orphan Salvation Association is among 
more than 100 HIV/AIDS programs that Johnson & Johnson supports across 50 countries.
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 Packaging plays an important role in 
protecting products as they are transported, 
stored and used. It is also critical in 
communicating user instructions and 
safety information. But natural resources 
are used to make and ship packaging, and 
after consumption of products, signiﬁ cant 
waste remains.
DESIGNING A SOLUTION
The best packaging, as deﬁ ned by the 
Sustainable Packaging Coalition—which 
Johnson & Johnson has belonged to since 
2005—is “sourced responsibly, designed to 
be eﬀ ective and safe throughout its life cycle, 
meets market criteria for performance and 
cost, is made entirely using renewable energy, 
and once used, is recycled eﬃ  ciently to 
provide a valuable resource for subsequent 
generations.” According to the Coalition, 
this deﬁ nition is a “target vision”—one 
that companies should strive toward.
 Mike Maggio, Vice President, 
Global Strategic Design Operations, 
Johnson & Johnson, says sustainability is a 
process: “There’s no beginning and no end 
to sustainability.” 
 Maggio explains: “We approach 
packaging with a continuous-improvement 
strategy that aims to reduce packaging 
weight and the energy used to make and 
transport packaging, as well as increase the 
portion of post-consumer recycled (PCR) 
materials and sustainable or biodegradable 
materials that we use.”
 An example of how this improvement cycle 
works is the packaging for our BAND-AID®
Brand Adhesive Bandages. In 2007, the box 
supplier in Brazil switched from non-certiﬁ ed 
paperboard to material that is certiﬁ ed by 
the Forest Stewardship Council (FSC). This 
year, we are working to reduce the size of the 
carton, and by next year, we hope to add post-
consumer recycled content to the paperboard.
 While Maggio focuses on packaging in 
the Johnson & Johnson Consumer Group 
of Companies, he has counterparts in the 
Medical Devices & Diagnostics (MD&D) 
and Pharmaceuticals businesses. As part of a 
broader product stewardship eﬀ ort, the goal 
throughout Johnson & Johnson is to reduce 
packaging weight, increase recycled content in 
packaging and eliminate materials of concern.
REDUCING PACKAGING WEIGHT
While we have successfully reduced the size 
and weight of many packages, any eﬀ ort to 
improve the sustainability of our packaging 
must involve people from procurement, 
engineering and quality assurance, as well 
as our suppliers and customers. Sometimes, 
challenges are uncovered.
 The iconic pink JOHNSON’S® Baby lotion 
bottle is one example. “Initially we set a goal 
for it to use more recycled materials—to 
contain more than 30 percent PCR high-
density polyethylene material in 2008,” 
says Maggio. “But quality is critical in the 
sustainability process, and we found we needed 
more time to meet the quality requirement.”
INCREASING RECYCLED CONTENT
Our Healthy Planet 2010 goal was to increase 
the percentage of environmentally preferred 
post-consumer recycled or certiﬁ ed ﬁ ber in 
oﬃ  ce paper and paper-based packaging. This 
goal has been met and exceeded (see page 24). 
But using recycled materials doesn’t just apply 
to paper; glass, certain plastics and metals can 
also be collected and used to manufacture 
packaging. For consumer packaging, 
Johnson & Johnson has established minimum-
PCR-content requirements for these materials. 
The same eﬀ orts are more diﬃ  cult with 
packaging in the MD&D and Pharmaceuticals 
businesses because of product registration 
and stability commitments.
ELIMINATING MATERIALS OF CONCERN
Similarly, we have goals to reduce our use of 
PVC (polyvinyl chloride) packaging. 
We distinguish between primary PVC 
Hundreds of millions of people each day throughout the world use 
our consumer products in their daily routines. And many more use our 
medicines and medical devices. What we do to reduce packaging, 
increase recycled content and eliminate materials of concern can 
have a signiﬁ cant impact on our earth.
E N V I R O N M E N T
Putting Thought
in a Package 
BIODEGRADABLE
CIALSO
REUSABLE
POST-
CONSUMER 
RECYCLED
CONTINUOUS PACKAGING 
IMPROVEMENTS
WEIGHT
REDUCTION
SUSTAINABLE
MATERIALS/
ENERGY
76617_L1_r2.indd   18 5/22/09   12:21:59 AM
19
S W E E T  O N  C H A N G E  In 2008 a change in the conﬁ guration of the SPLENDA® package
saved 1.7 million tons of paperboard. Gary Short, Contract Site Manager, McNeil
Nutritionals, handles supply chain relations and works with Kelley Frank, Associate
Packaging Director, OTC & Nutritionals, Johnson & Johnson Strategic Design, LLC
to achieve the Company’s packaging goals.
SEGMENT TYPE OF PACKAGING 2010 GOAL PROGRESS
Consumer Products Primary 100 percent
elimination1
90 percent eliminated
(2,232 tons)2
Consumer Products Secondary
& tertiary
100 percent
elimination
85 percent eliminated
(784 tons)
Medical Devices &
Diagnostics
Secondary
& tertiary
100 percent
elimination 100 percent eliminated
Pharmaceuticals Secondary
& tertiary
100 percent
elimination
1 percent eliminated
(230 tons)3
1 Does not include over-the-counter drug products
2 This business made a large acquisition in 2007 that added PVC into its baseline in the middle of the goal period
3 We have 33 tons of PVC remaining in secondary packaging for two products
packaging—that which comes into direct
contact with our products —and secondary
or tertiary packaging, such as bottle cap seals
or palletizing wrappers. Replacing primary
PVC is more diﬃ cult because PVC has
characteristics that protect product quality.
In general, eliminating PVC from primary
packaging requires signiﬁ cant time and cost to
test and validate alternatives. Nonetheless, we
are making good progress on our stated goals
(see chart at right).
OUR PATH FORWARD
In planning for the future, Mike Maggio
and his team in our Consumer business are
considering biodegradable and reﬁ llable
packaging. “Right now, biodegradable
packaging is mostly used by the food and
beverage industry, where short shelf life
and well-deﬁ ned distribution channels
make it feasible. We’re not there yet,” says
Maggio, “but we’re considering the kinds of
biodegradable materials that are out there and
how we might be able to use them.”
Reﬁ llables might see their ﬁ rst use in
emerging markets. “We’re ﬁ nding consumers
there want to buy smaller quantities with less
initial packaging, then reﬁ ll the same container
later,” says Maggio. “In 2008, we developed
Guidelines for Reusability, which address the
quality procedures needed to make reﬁ llable
packaging viable. A number of our brands are
now exploring reﬁ llables.”
ENCOURAGING CHANGE
Maggio says he’s seen a shift in the last
three years. Instead of his team pushing
for sustainability goals, marketing teams
are now eager to see how they can help
their brands meet the greening tastes
of consumers. But growing consumer
interest is just one driving factor. “Some
of our biggest customers—Wal-Mart,
Tesco (in the U.K.) and Costco—are very
tuned in and are helping us with their
scorecards and measures to make continual
improvements,” says Maggio.
In turn, Johnson & Johnson is exercising
leadership with our suppliers through our
Standards for Responsible External
Manufacturing and a Procurement
Sustainability Initiative, which are driving
sustainability into the conversations we
have with suppliers.
“Sustainable materials and methods
are an increasingly important element
in our relationship with suppliers,” says
Andrew Mowery, Vice President, Packaging
Category Leader, Johnson & Johnson. “It’s
important that we communicate with our
suppliers about our goals and expectations
for supply chain partners.” Through our
participation in programs such as the
Carbon Disclosure Project’s  Supply Chain
Leadership Council and the EPA’s Green
Supplier Network, we are encouraging
suppliers to measure and reduce
their environmental footprint.
“We don’t know if we’re leaders; we’re
more concerned with doing what we know
are the right things to do,” says Maggio.
“The biggest challenge is what we don’t
know—it means we must continue to stay
in touch with new technologies and to
assess new opportunities.”
P U T T I N G T H O U G H T I N A P A C K A G E
PVC PACKAGING GOALS
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 From diminishing quality to droughts, 
many parts of the world are already 
experiencing water challenges. 
 In 2008, Johnson & Johnson used 
approximately 3 billion gallons of 
water—enough to ﬁ ll 4,600 Olympic-sized 
swimming pools—in our manufacturing 
processes and our oﬃ  ce facilities. In 2005, 
we set a Healthy Planet 2010 goal to reduce 
absolute water use by 10 percent from 
2005–2010, and we are measuring our 
progress against this goal (see chart at right).
 “Water is a critical natural resource, and 
we’re always mindful of ways to protect 
water quality and use water wisely,” says 
Brian Boyd, Vice President, Worldwide 
Environmental Health and Safety. “While 
conservation is front-of-mind, true 
stewardship requires a more comprehensive 
water-management strategy.”
WATER MANAGEMENT 
STRATEGY
The corporate environmental group 
provides business leaders with tools 
and best practices in water conservation 
so they can select approaches that will 
best reduce water use and costs. Each 
Johnson & Johnson facility is required to 
develop a water conservation plan and 
perform an assessment to identify ways to 
reduce water use. “Some places where we 
operate, like China and India, don’t have 
abundant water,” says Boyd.  
DOING MORE WITH LESS
“Our biggest successes in reducing the 
use of water have come from two areas: 
projects aimed at controlling cooling at our 
sites in energy-eﬃ  cient ways and process 
changes or improvements,” says Keith 
Wojciechowski, Senior Environmental 
Engineer. He shares an example: “Cilag 
AG, our pharmaceutical manufacturing 
facility in Switzerland, reduced its water 
use 35 percent by reusing coolant, reducing 
Johnson & Johnson’s total water use by 
nearly 3.5 percent.” In another example, 
Wojciechowski said, an Ethicon facility 
found that by separating scrap needles 
returned with packaging for reuse, the 
amount of water used for sorting and 
cleaning was reduced. 
OTHER WAYS TO SAVE
We anticipate that further process improve-
ments will drive continued progress toward 
the Healthy Planet 2010 water reduction goal, 
and additional eﬀ orts to reuse or recycle 
water could further reduce our water use. 
“Our challenge is to continue to reduce 
water consumption, even as production is 
increasing,” says Wojciechowski.1 
THE BIGGER WATER PICTURE
“With water we must continue to take a 
long-term view,” says Boyd. For example, 
we are actively working on the issue of 
pharmaceuticals in the environment (PIE). 
PIE is gaining attention, as trace amounts 
of pharmaceuticals have been found in 
water in the U.S. and Europe. The main 
source of PIE is excretion of medicines as 
a result of normal patient and consumer 
use. Substantial research indicates that it is 
unlikely the amounts found aﬀ ect human 
health. However, there is some indication 
that aquatic organisms may be aﬀ ected with 
long-term exposure. 
 Additional research is needed to 
properly evaluate the potential risks, and 
Johnson & Johnson is actively engaged 
on this issue. The company is funding a 
study underway with the National Science 
Foundation and several universities to look 
at cost-eﬀ ective PIE treatment methods 
that governments can employ. “Where we 
can, we change our behaviors, and where the 
issue is broader than we can solve, we get 
involved with others to understand the best 
possible long-term approaches,” says Boyd. 
 Evaluating the potential risks of PIE is 
a complex undertaking. In the meantime, 
Johnson & Johnson is taking steps to 
minimize or eliminate sources of active 
pharmaceutical ingredients (APIs) from 
our wastewater discharges. Periodic 
wastewater monitoring is conducted to 
evaluate predicted concentrations and 
to identify potential toxicity to anything 
that lives in water. Further, we develop 
safe levels —known as Predicted No Eﬀ ect 
Concentrations, or PNECs—for our APIs. 
At the end of 2008, most of our operating 
companies that use APIs had characterized 
their wastewater eﬄ  uents; this information 
is being used to devise a comprehensive risk- 
management strategy. 
Keeping Water Vital
E N V I R O N M E N T
After climate change, water may be the world’s most pressing 
environmental challenge. Whether it’s the water we use in our 
facilities or the water people drink, Johnson & Johnson knows that 
clean water, and enough of it, is critical to health. 
WASTEWATER TREATMENT IN INDIA 
India is an important emerging market and a part of the world where water scarcity and quality 
are pressing issues. It’s expected that manufacturing and exports will increase substantially
by 2010, with important environmental implications, particularly as regards water quality. 
 The Johnson & Johnson, Ltd. consumer manufacturing facility built in Baddi, 
Himachal Pradesh in 2006 included a zero-discharge wastewater-treatment facility—
every bit of treated water is reused for irrigation, garden use and toilet ﬂ ushing. 
 The facility has also begun rain-harvesting. Rooftop rainfall is collected and recharged 
to the ground through a rainwater-harvesting pit. “The huge amount of water during 
monsoon season was going directly to the storm water and was wasted,” says 
Achal Gupta, Manager, Environment Health and Safety, Johnson & Johnson, Ltd. 
“So we decided to make use of it.” 
1For a sampling of our environmental eﬀ orts around 
the world, see the interactive map on www.jnj.com/
connect/caring/environment-protection.
K E E P I N G  C O O L  Mladen Loncar, Project 
Manager, Global Pharmaceutical Supply 
Group, LLC, and his colleagues at Cilag AG 
in Switzerland reduced water use by 35 
percent using coolant instead of fresh water 
in a specially designed closed-loop chiller.
Figures represent small corrections as a result of 
routine auditing of our data.
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Environmental
Performance
E N V I R O N M E N T
ENERGY USE  Gigawatt hours (GWH)
DIRECT INDIRECT TOTAL
% FROM RENEWABLE 
ENERGY SOURCES
1990 1,527 1,340 2,867 0 percent (baseline)
2006 1,975 1,811 3,786 37 percent
2007 2,030 1,818 3,848 36 percent
2008 2,021 1,882 3,903 34 percent
CARBON DIOXIDE NET EMISSIONS  Thousand metric tons
DIRECT INDIRECT
INDIRECT
OFFSETS
NET EMISSIONS
1990 308 751 0 1,059
2006 341 937 395 883
2007 344 973 385 932
2008 357 971 364 963
MANAGEMENT OVERVIEW 
Environmental management 
at Johnson & Johnson is 
guided by Our Credo, our 
environmental policy and our 
global environment standards.1  
In addition to the topics discussed 
on pages 18 through 21,  the 
following section includes other 
aspects of our environmental 
performance in 2008.
CERTIFICATION
All our manufacturing and 
research and development 
facilities around the world 
are certiﬁ ed to the ISO 14001 
Environmental Management 
System. This is a third-party 
system that follows a “plan-do-
check-act” approach to drive 
continual improvement in the 
management of environmental 
performance. 
 Johnson & Johnson also 
has global standards and a 
complementary auditing 
process that includes self-
assessment, independent 
assessment, action planning, 
corrective action tracking and 
training. Sites conduct annual 
compliance audits, and, generally 
every third year, an independent 
team evaluates both compliance 
and management systems. 
An event notiﬁ cation process 
alerts management of 
environmental noncompliances 
and accidental releases within 
72 hours. 
 Johnson & Johnson has been 
setting long-term (ﬁ ve-year) 
environmental goals since 
1990. Our Healthy Planet 2010 
goals aim to reduce carbon 
dioxide emissions, water use 
and waste generation. We 
have targets to source oﬃ  ce 
paper and paper packaging in a 
more sustainable way, and we 
have also set goals in product 
stewardship, environmental 
literacy, transparency, 
biodiversity, compliance and 
external manufacturing. These 
categories were chosen after 
consideration of our areas of 
environmental impact and 
with input from stakeholders, 
including government oﬃ  cials, 
environmental groups, other 
companies and academic 
thought leaders. 
STRATEGY DEVELOPMENT 
We conduct periodic bench-
marking with peers, monitor 
developing science and regulation, 
convene an Emerging Issues 
team to better understand issues 
on the horizon, and cultivate 
environmental partnerships. All 
these approaches enable us to 
adapt our strategies to protect the 
environment and enhance the 
sustainability attributes of our 
products. 
OVERSIGHT
Our environmental strategy 
and performance are reviewed 
annually with the Executive 
Committee and with the Public 
Policy Advisory Committee of our 
Board of Directors. In addition, 
our environmental performance 
is reviewed quarterly with 
COMPLIANCE 2005 2006 2007 2008
Accidental Releases (number of events) 9 9 9 15
Agency-Issued Noncompliances 
(number of events)
18 10 13 20
Fines Paid (thousands $U.S.) 5.82 5.58 31.4 164.1
the Corporate Compliance 
Committee. 
 To drive our environmental 
eﬀ orts, each Group Operating 
Committee has goals and plans 
for environmental compliance.  
Goals are reviewed by the Oﬃ  ce 
of the Chairman, approved 
by the Board of Directors 
and monitored by the Public 
Policy Advisory Committee 
of the Board. Our Corporate 
Compliance Committee also 
provides ongoing oversight. 
Signiﬁ cant issues are escalated to 
Executive Committee members 
and monitored until successfully 
resolved.
  
COMPLIANCE 
Johnson & Johnson aspires 
to have zero accidental 
environmental releases, 
zero noncompliances and 
thereby zero ﬁ nes.  In 2008, 
our performance in this area 
trended slightly upward (see 
chart above). While all these 
events continue to be minor 
in nature (e.g., wastewater 
limits, reports submitted late), 
we have asked our companies 
for increased vigilance to 
reduce the occurrence of these 
noncompliance events. We will 
be watching these indicators 
through 2009 to gauge whether 
the trend is just a minor 
statistical variation or if we need 
changes in our management 
system. 
 During 2008, we settled two 
cases that were under discussion 
with regulatory agencies. 
Noramco Inc. in Wilmington, 
Delaware, paid $125,934 to settle 
penalties from a hazardous-waste 
violation that occurred in 2006 
and an air emission violation in 
2007. Information Technology 
Services in Raritan, New Jersey, 
paid $38,122 in ﬁ nes for air 
emissions that occurred in 2004 
and 2005.
CLIMATE CHANGE 
In 2003, Johnson & Johnson 
adopted a Climate Friendly 
Energy Policy, which established 
greenhouse gas reduction goals 
and outlined a pathway to achieve 
them. It is supported by a carbon 
dioxide (CO2) reduction capital 
In 2008, 34 percent 
of the electricity used 
by Johnson & Johnson 
operating companies 
was from renewable 
resources.
1 www.jnj.com/connect/caring/
environment-protection
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funding process that makes
$40 million per year available
for energy and greenhouse
gas reduction projects across
the company. We have targets
for facility emissions and
transportation-related emissions.
FACILITY EMISSIONS
Our Healthy Planet 2010  goal for
emissions from our company-
owned facilities is a 7 percent
absolute reduction in CO2 from
1990–2010. To achieve this goal,
Johnson & Johnson operating
companies are improving energy
eﬃ ciency, installing on-site
cogeneration and renewable
energy infrastructure, and
purchasing green power and
carbon oﬀ sets (see chart above).
We are currently meeting this
goal, having achieved a 9 percent
absolute reduction in CO2
emissions from 1990–2008 in our
company-owned facilities (see
chart at bottom left). During this
same period, sales grew by more
than 400 percent.
We fully anticipate meeting
our 2010 goal, despite challenges
such as reducing our absolute
emissions while our business is
growing and ﬁ nancially justifying
energy-reduction projects when
energy prices are down. RECs and
carbon oﬀ sets provide a mecha-
nism for us to support renewable
energy projects to reduce green-
house gas emissions through
external projects supported by
Johnson & Johnson, similar to the
approach that would be employed
under a cap and trade system. Still,
our preference is to reduce our
direct emissions when possible.
SUPPLY CHAIN & GHG
We are working to inﬂ uence our
supply chain with regards to
greenhouse gas (GHG) emissions
by encouraging our suppliers
to join the Carbon Disclosure
Project’s (CDP) Supply Chain
Leadership Council. We have
been disclosing our energy
use to the CDP since 2003
and believe that doing this
inventory and understanding a
company’s emissions is the ﬁ rst
step in managing them better.2
The operating companies of
Johnson & Johnson want to do
business with suppliers and
external manufacturers that
share our commitment to reduce
greenhouse gases.
CLIMATE POLICY
INITIATIVES
We are also using our inﬂ uence
to help shape responsible
climate and energy policy. We
are a member of the U.S. Climate
Action Partnership (USCAP). In
early 2009, USCAP released policy
recommendations for developing
legislation that would create
a national climate protection
program. In addition, Johnson &
Johnson was one of approximately
140 companies to sign the Poznan
Communiqué in 2008, at the
United Nations Climate Talks in
Poland. The communiqué seeks
a global, integrated solution to
climate change.
FLEET EMISSIONS
At the end of 2008, the
Johnson & Johnson worldwide
automobile ﬂ eet consisted of
approximately 36,000 owned or
leased vehicles, accounting for an
estimated 250,000 metric tons of
CO2 from 741 million miles driven.
These emissions are not included
in our worldwide CO2 emissions
ﬁ gure, as we do not yet have an
adequate degree of precision in
these measurements.
OWNED/LEASED CARS
Our Healthy Planet 2010  goal is
to reduce total CO2 emissions per
kilometer driven by 30 percent
from our 2003 baseline, with
a current target of 150 grams/
kilometer CO2 worldwide. To
meet the goal, we have set
minimum fuel-eﬃ ciency
requirements by vehicle category,
and we are purchasing hybrid
electric cars and ethanol-fueled
vehicles to replace older, less-
eﬃ cient models.
At the end of 2008, we had
more than 2,100 hybrid vehicles
in our U.S. ﬂ eet (approximately
20 percent of the total U.S.
ﬂ eet). Johnson & Johnson was
recognized by Automotive Fleet
magazine as the No. 1 commercial
hybrid ﬂ eet in the U.S. Also, 100
percent of our automotive
purchases are made through
minority suppliers, which
supports our aim of diversifying
our supply chain. (See “Supplier
Diversity” on page 17.)
Despite our success
incorporating hybrid vehicles
into our U.S. ﬂ eet, our CO2
emissions per unit distance
actually increased, to an
average 233 grams/kilometer.
There are several reasons for
this, including the fact that
we have not yet cycled some
less-eﬃ cient vehicles out of
our ﬂ eet and we need to retain
minivans to transport medical
devices and supplies. We are
taking steps to accelerate our
transition to a more eﬃ cient
ﬂ eet. We acknowledge that
our goal was more aggressive
than anticipated, and it will be
a challenge to meet it by 2010.
Nonetheless, we continue to
work toward it, and we are
exploring options to make
progress in this area.
SHIPPING TRUCKS
Our environmental eﬀ orts for
transportation also extend to
product shipments. The Global
Transportation Organization, a
division of the Johnson & Johnson
Sales and Logistics Company,
LLC, which handles shipping for
our three business segments, is
participating in the U.S. EPA’s
SmartWay program. SmartWay
is a voluntary collaboration to
increase transportation energy
ENERGY
EFFICIENCY
1 7
HVAC
5
CHILLER
UPGRADES
1 5
BOILER
UPGRADES
4COGENERATION8
SOLAR P.V./
THERMAL
8
BIOMASS
3
WIND
1
Investing in Lower-Carbon Energy Efficiency
Approved Energy-Reduction Projects
As of December 2008, 61 energy-reduction projects were approved through our capital
funding process. Of these, 45 were completed from 2005–2008, and 16 are underway now.
For approximately $124 million in capital, we anticipate these projects will collectively reduce
CO2 emissions by 118,000 tons and provide a 17.2 percent average rate of return.
2 See our reports at www.cdproject.
E N V I R O N M E N T A L P E R F O R M A N C E
H A R N E S S I N G  S O L A R
P O W E R In 2008, the World
Resources Institute reported
that Johnson & Johnson was
the second largest corporate
user of on-site solar power in
the United States
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C H I L D R E N  S H A R E  C O N C E R N
F O R  U S I N G  E N E R G Y  W I S E LY 
This winning artwork 
from the 25th annual 
Johnson & Johnson Global 
Energy coloring contest 
reminds us that our actions to 
address climate change today 
uphold our responsibility to 
future generations. 
• Water:  Increase eﬃ  ciency
• Energy:  Increase eﬃ  ciency
• Packaging  Reduce weight, 
increase recyclability, eliminate 
materials of concern
• Innovation:  Create break-
through, best-in-class products 
and services.
 Johnson & Johnson has two  
Healthy Planet 2010  product 
stewardship goals. The ﬁ rst is 
that each operating company 
establish a plan to evaluate and 
use ingredients and materials 
with an improved sustainability 
proﬁ le. The second establishes 
“take-back” mechanisms for 
our electronic products, to 
enable improved recycling 
or remanufacturing of these 
products after their useful life. 
 At the end of 2008, each of our 
companies had a wide range of 
activities underway to improve 
the sustainability of its products. 
For example, we eliminated 1.4 
million kilograms of solvent 
from the manufacture of our new 
AIDS drug in 2008 by reusing 
solvents in a fully compliant 
fashion. Additionally, 54 percent 
of our businesses (calculated on a 
regional basis) have implemented 
take-back programs, up from 21 
percent in 2007. To advance this 
capability, a global agreement 
with one of the largest electronic 
take-back companies was 
developed and will go into full 
eﬀ ect in 2009.      
PAPER & PACKAGING 
One of the ways we work to 
enhance the environment is 
by using our purchasing power 
to enhance responsible forest 
management. We are a member 
of the World Wildlife Fund’s 
North America Forest and Trade 
Network and the Global Forest 
& Trade Network, both of which 
have helped us understand 
current threats to our forests and 
the many ways we can work to 
protect them. 
 We established a  Healthy 
Planet 2010  goal to have 
90 percent of our oﬃ  ce paper 
and 75 percent of our paper-
E N V I R O N M E N T based packaging contain greater 
than 30 percent post-consumer 
recycled (PCR) content or ﬁ ber 
from certiﬁ ed forests. At the end 
of 2008, 93 percent of packaging 
and 96 percent of oﬃ  ce paper met 
this goal. 
 Similarly, we have been 
reducing the use of polyvinyl 
chloride (PVC) in packaging. 
For details, see page 19. 
WASTE REDUCTION & 
LIABILITIES
Johnson & Johnson recognizes 
that waste in a production 
process signals ineﬃ  ciency. We 
have a Healthy Planet 2010 goal 
to reduce hazardous and non-
hazardous waste in our company-
owned facilities by 10 percent 
against our 2005 baseline. We are 
currently meeting these targets. 
In 2008, we reduced both non-
hazardous and hazardous waste 
by 16 percent (see chart at top 
right on page 25).
 Our operating companies 
have increased recycling, and they 
are successfully reusing some 
hazardous and non-hazardous 
waste. One example is identifying 
beneﬁ cial reuse markets for the 
recycling of our solvent-based 
hazardous waste. 
 In 2008, 1.2 million pounds 
of waste solvent was captured 
and reclaimed. Similarly, 
ethanol-containing rinse 
RECYCLED
20,518
BIOLOGICAL/
CHEMICAL 
TREATMENT
1,628
ENERGY 
RECOVERY
19,462
INCINERATED
5,511
LANDFILLED
2,822
REUSED
154
Off-site Management of Hazardous Waste
(in thousands of kilograms)
Total: 50,094,567 kg
tons of capacity by 2015,  ﬁ ve 
years ahead of the schedule set 
out by the Montreal Protocol. 
We are completing an emissions 
inventory and identifying 
acceptable alternative 
technologies. 
PRODUCT STEWARDSHIP  
Product stewardship means tak-
ing responsibility for the environ-
mental and social impacts of our 
products across their full lifecycle. 
One way our companies do that 
is by using our Design for Envi-
ronment tool, which helps our 
scientists and marketers assess 
products, processes and packag-
ing for environmental impacts. 
 In 2008 we revised the tool to 
align with a new product lifecycle 
assessment scorecard we are roll-
ing out in 2009. This scorecard 
will help operating companies 
uncover areas of product impact 
vulnerability or opportunity 
to create greener products. It 
will also help companies avoid 
greenwashing errors, should they 
decide to make environmental 
statements about products. 
Products are rated on six criteria:
• Materials:  Use safer ones,
 less volume or weight and fewer 
materials
• Waste:  Decrease waste 
generation, increase recyclability 
and reuse
eﬃ  ciency while decreasing 
greenhouse gas emissions and air 
pollution. 
 During 2008, we increased 
our business with SmartWay-
approved carriers. More 
than 95 percent of trucking 
expenditure is with SmartWay-
approved carriers (up from 72 
percent), and more than 77 
percent of our total truckload 
business is with carriers rated 
exceptional by SmartWay.
 Another important initiative 
in 2008 was use of  day cabs 
(trucks without the sleeper cab) 
to transfer heavy shipments 
of LISTERINE® from our 
manufacturing facility to the 
distribution center 200 miles away. 
The day cab project eliminated 75 
trucks from the highway. Overall, 
our 2008 eﬀ orts removed 1,070 
trucks from the highway and 
prevented over 7,500 tons of CO2 
from entering the atmosphere. 
OZONE-DEPLETING 
SUBSTANCES
Johnson & Johnson has 
committed to reduce our 
use of substances that harm 
the ozone layer, such as 
hydrochloroﬂ uorocarbons 
(HCFCs), used in facility 
refrigeration equipment. 
Our plan is to eliminate use 
of these substances in 
equipment greater than ﬁ ve 
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waters, previously disposed of
as hazardous waste, are now
captured from our LISTERINE®
processing lines and
reconditioned. As technology
identiﬁ es ways to recycle many
wastes, those we previously
disposed of are becoming a
commodity or, as in the case
of high-BTU wastes, an energy
source. We also continue
to identify opportunities to
reduce waste generation at
its source.
Over the years,
Johnson & Johnson has been
named as a potentially respon-
sible party for 26 hazardous waste
disposal sites, and we have
accrued approximately $9 million
in environmental liabilities.
We are involved in these sites
either because of past waste
management practices that were
standard industry practice at the
time  or because of improper han-
dling of our waste by companies
with which we contracted. During
2008, we spent approximately
$4.6 million to address remedia-
tion at 21 existing and divested
Johnson & Johnson properties;
we completed remediation at
three sites.
BIODIVERSITY
As a way to foster biodiversity,
Johnson & Johnson set a Healthy
Planet 2010  goal to implement
biodiversity conservation plans
at 100 percent of our facilities and
companies by 2010. At the end of
2008, all our operating companies
had a biodiversity plan endorsed
by company leadership.
More than 55 conservation
projects are underway around the
world; 66 percent aim to enhance
or conserve biodiversity oﬀ -site.
Our current challenge in
meeting this goal is ﬁ nancial,
as resources are scarcer in
today’s economic climate.
However, many of these projects
are accomplished through
volunteer time and resources.
As an example, employees from
Johnson & Johnson Consumer
Products Company Canada, in
humans depend on biodiversity
and argues that we can no longer
see ourselves as separate from
the natural world, nor assume
we will be unharmed by its
alteration.
EMPLOYEE EDUCATION
One of our Healthy Planet
2010 goals is to conduct
annual environmental literacy
campaigns throughout
our operating companies.
Educational materials and
approaches included posters,
calendars, web-conferencing,
articles, videos, e-learning
modules, brochures, social
media sites and some materials
speciﬁ cally created for the
children of our employees.
Through the literacy program,
our employees become aware
of global environmental issues
E N V I R O N M E N T A L P E R F O R M A N C E
Montreal, have restored 867
acres of the Sainte-Marguerite-
Marie peat lands in partnership
with the Canadian Peat Industry,
the Canadian and Quebec
governments and the Peatland
Ecology Research Group. The
company once used peat from
these lands as the absorbent core
in sanitary napkins.
CONSERVATION
PARTNERSHIPS
Johnson & Johnson has
longstanding relationships with
many conservation organizations,
including the World Wildlife
Fund (WWF), Conservation
Fund, the Trust for Public
Land, Wilderness Society and
the Harvard Medical School
Center for Health and the Global
Environment.
In 2008, we entered into
a Global Development Alliance
with the World Wildlife Fund
and the U.S. Agency for
International Development.
By combining USAID support
for family planning and repro-
ductive health with support
from Johnson & Johnson for
the environment and human
health, the Alliance enables
WWF to work more eﬀ ectively
with local communities to con-
serve important species and
ecosystems. In Nepal, the
Alliance has worked with forest
users to enhance health and to
replace ﬁ rewood with biogas
as a fuel source. The Alliance is
also conserving key ﬁ sheries on
the northern coast of Kenya and
improving the health of com-
munities using those ﬁ sheries.
Also in 2008, a project of
the Harvard Medical School
Center for Health and the Global
Environment, supported by
Johnson & Johnson, resulted
in the publication of Sustaining
Life: How Human Health Depends
on Biodiversity. The ﬁ rst book
to examine the full range of
potential threats that a loss of
biodiversity poses to human
health, Sustaining Life presents
a comprehensive view of how
50
40
30
20
0
Waste (in millions of kilograms)1,2
2005
60
70
Non-hazardous waste
Hazardous waste
1 Figures reflect small corrections as a result of routine auditing of our data
2 Disposed off-site, excluding recycle and reuse
2006 2007 2008
61.8
35.2
56.9
39.6
54.0
34.2
51.7
29.4
SUSTAINABLE
FORESTRY
44%
HEALTHY
PLANET 2010
GOALS
17%
CLIMATE
CHANGE
9%ENERGY
9%
BIO-
DIVERSITY
7%
SUSTAIN-
ABILTY
6%
WATER
CONSERVATION
2%
OTHER
6%
Environmental Literacy Programs
During 2008, 97 percent of our facilities ﬁ elded environmental
literacy programs across various topic areas.
and formulate workable
ideas that help us reduce our
environmental impacts.
TRANSPARENCY
We continue to make progress
on our Healthy Planet 2010
goal to have 100 percent of
manufacturing and research and
development facilities providing
facility- or company-speciﬁ c
environmental sustainability
information to the public. At
the end of 2008, 85 percent
of our facilities had created
transparency reports, which are
being posted to jnj.com. We do
not expect to achieve the 100
percent goal by 2010 because
our mix of facilities is constantly
changing through acquisition and
divestiture. Most of the
non-reporting facilities fall into
one of these situations.
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A Focus on Wellness
& Prevention
Governments, private payers, employers, 
unions and individuals are seeking new 
solutions to spiraling health care costs. 
 Businesses such as ours face these and 
other challenges too: patent expirations and 
generic competition for some pharmaceutical 
products; aggressive new competitors in 
some of our surgical and comprehensive care 
businesses; and low-cost brands ﬁ ghting for 
market share with our consumer products. 
 Still, Johnson & Johnson remains 
committed to expanding the ways in 
which we care for people throughout the 
world. We’ve made signiﬁ cant strides to 
strengthen market positions in the areas in 
which we compete today, identifying new 
high-growth opportunities and broadening 
our capabilities into more of the $4.1 trillion 
health care market.
 Many of today’s burgeoning health care 
costs are related to lifestyle-driven chronic 
disease, both in developed and developing 
countries. In the U.S., 78 percent of health care 
spending is for preventable chronic conditions. 
So as Johnson & Johnson expands its business, 
disease prevention is both a signiﬁ cant 
business opportunity and an important way 
to deliver on our mission of enhancing lives 
around the world. 
DISTINCT GROWTH OPPORTUNITY
In November 2007 we began to identify new 
growth opportunities beyond our existing 
pharmaceutical, medical device, diagnostics 
and consumer businesses. As a result, we 
established a Wellness & Prevention platform 
in late 2008 that, as its ﬁ rst goal, will provide 
products and services designed to help 
employers optimize the health of employees.
 “We’re building a portfolio of products 
and services that will help prevent chronic 
disease, sustain wellness and restore 
faculties to the aging,” says Calvin Schmidt, 
President, Wellness & Prevention, Inc., a 
Johnson & Johnson company. “We’re starting 
with employers—our products and services 
will help them oﬀ er programs that empower 
people to be well and perform at their best.”
WELLNESS & PREVENTION
The ﬁ rst steps in the Wellness & Prevention 
initiative were two acquisitions in late 2008. 
In October, Johnson & Johnson acquired 
HealthMedia, Inc., a provider of web-based 
programs that help people improve their 
behaviors in areas such as weight and 
stress management, sleep quality, smoking 
cessation and taking medication as directed 
by their health care provider. HealthMedia 
combines advanced technology and 
behavioral science to eﬀ ectively emulate 
a health coach via the web. Results include 
increased compliance with treatment 
regimens, reduced use of medical systems 
and increased productivity. HealthMedia’s 
products also have demonstrated cost savings 
for health plans and employers. 
 In December, Johnson & Johnson 
acquired Human Performance InstituteTM, 
which oﬀ ers a unique combination of tools 
such as performance psychology, exercise 
physiology and nutrition to achieve health 
goals. This approach has been shown to 
have a positive impact on performance in 
B U S I N E S S
Johnson & Johnson has identiﬁ ed Wellness & Prevention as a 
platform for growth because health care systems around the world, 
as well as individuals, are seeking products and services that can 
reduce preventable chronic disease, sustain good health and 
well-being, and restore faculties to otherwise healthy aging people. 
A  F O C U S  O N  W E L L N E S S  &  P R E V E N T I O N
JOHNSON & JOHNSON 
EMPLOYEE HEALTH INDICATORS
BY % OF PROFILED U.S. EMPLOYEES
HEALTH RISK
1995-1999 
AVERAGE 2007-2008 
Smoking 12% 4.2%
High blood pressure
(>140/90)
14% 6.4%
High cholesterol
(>240 mg/dl)
19% 7.2%
Inactivity 
(30 minutes of activity less 
than 4 days/week)
39% 31.5%
FA M I LY  W E L L N E S S  Seen here with 
his family, Calvin Schmidt is heading 
Johnson & Johnson’s newest business 
platform, Wellness & Prevention, Inc. It’s 
one way Johnson & Johnson is expanding
care for people throughout the world.
high-stress arenas such as business, sports, 
medicine and law enforcement. 
 Johnson & Johnson believes there is 
substantial strategic synergy between 
HealthMedia, Inc. and Human Performance 
InstituteTM. 
PROVEN POTENTIAL 
Initially, the Johnson & Johnson 
Wellness & Prevention platform is directed 
at employers, which, in the United States, 
bear a signiﬁ cant share of the cost of 
health care beneﬁ ts. As a major employer, 
Johnson & Johnson has focused on the 
beneﬁ ts of wellness and prevention with 
our own workforce and has achieved 
documented savings and improved 
productivity. 
 Johnson & Johnson employees have 
used HealthMedia products since 2003, 
and roughly 8,000 U.S. employees have 
participated in one or more programs. 
Success is measurable: For example, 
58 percent of participants in a stress- 
management program saw improvement 
in six months; 42 percent of employees in 
a smoking-cessation program quit within 
six months; and 55 percent of those in a 
weight-loss program had success, with 
35 percent of participants reducing BMI 
(Body Mass Index) by one point or more.
 Our focus on health and wellness among 
our U.S. workforce has helped reduce 
per-capita health-plan costs by $400 per 
employee per year (based on 2007 data) 
and signiﬁ cantly improved overall 
employee health and productivity. 
 The Johnson & Johnson Wellness 
& Prevention platform recognizes the 
opportunity to fundamentally expand 
the deﬁ nition of health care. And while 
reducing costs is certainly one beneﬁ t of 
prevention, there’s more. “Preventing 
disease means preventing pain and 
suﬀ ering, and helping people lead healthier, 
more productive lives. That’s a tremendous 
and inspiring goal,” says Schmidt.
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Developing 
New Markets
 Although the U.S. remains the world’s 
leading health and professional care market, 
the most dramatic product growth rates are 
occurring in the world’s emerging markets, 
in countries such as Brazil, Russia, India and 
China—the BRIC countries—as well as other 
rapidly developing countries, such as Turkey 
and Mexico.
 While the current economic crisis 
may temper growth in these markets, 
opportunities remain signiﬁ cant. Over the 
next ﬁ ve years, Russia, India, China and 
Turkey are projected to grow at high single-
digit rates, while more developed markets are 
likely to grow more slowly. 
 Patients and consumers in developing 
markets are increasingly sophisticated, but 
sometimes the products that will best meet 
their needs are diﬀ erent from those that sell 
in developed markets. 
WELL-ESTABLISHED PRESENCE 
Serving the needs of local consumers is 
something that a decentralized, close-to-
the-ground company can do well, and we 
are not newcomers to emerging-market 
countries. Johnson & Johnson has maintained 
a signiﬁ cant and well-established presence 
in these markets for decades, using our 
decentralized operating model to stay close 
to patients, consumers and health care 
providers with local market insights, products 
and strategies. We began operations in Brazil 
and India in the ’30s and ’40s and in China and 
Russia in the ’80s and ’90s. Our commitment 
to these markets continues to grow. 
 There are three core components to 
our emerging-market strategy: developing 
market-appropriate products to better 
meet local needs; building local research 
and development, marketing and other 
capabilities to fully integrate with the market 
and its people; and, in our professional 
businesses, training health care practitioners 
to provide optimal patient care. 
MARKET-APPROPRIATE PRODUCTS
What satisﬁ es needs in developed markets 
often isn’t what makes a product appropriate 
in an emerging market. Here, the emerging 
middle-class or mid-tier consumer—people 
whose incomes are rising beyond a lifestyle 
that is paycheck-to-paycheck—has a new 
opportunity to focus on things like health care. 
The mid-tier consumer’s values and needs 
present diﬀ erences to developed markets. 
 A consumer bonding program at the 
Emerging Market Research Center in China 
includes a live-in program, where researchers 
spend time with a family to get to know 
their needs in ways they might not articulate. 
“Emerging-market consumers have diﬀ erent 
living environments, life attitudes, and 
education, which results in diﬀ erent needs for 
products and communication,” says Lillian 
Xu, Consumer Science Manager, Asia Paciﬁ c 
& Emerging Markets, Johnson & Johnson 
Consumer Group of Companies. “We felt 
that it’s critical to get close to consumers 
in these markets and even ‘live in their skin 
and think in their way’ in order to develop 
products that really meet their needs.” 
 There has already been success with baby 
and sanitary-protection products geared 
toward mid-tier consumers. “We’re expanding 
our eﬀ orts,” says Colleen Goggins, Worldwide 
Chairman, Johnson & Johnson Consumer 
Group of Companies, referencing the 2008 
acquisition of Beijing Dabao Cosmetics, Ltd., 
a leading Chinese skin care company. “Dabao 
adds new products to our mid-tier portfolio 
and extends our reach deep into China’s urban 
heartland.” 
LOCAL CAPABILITIES 
The Dabao acquisition is the most recent 
example of the work Johnson & Johnson 
B U S I N E S S
One of our business priorities at Johnson & Johnson is to accelerate growth 
in emerging markets—not only to bring value to the Company but also to 
serve the needs of these important new customers.
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is doing to build local capabilities in one 
of several important growing health care 
markets: China. Johnson & Johnson has 
had businesses and health care education 
activities in China for more than 20 years. 
More recently, the Company served as an 
oﬃ  cial health care sponsor of the Beijing 
2008 Olympic Games and Paralympic 
Games, adding  to its community health 
programs support for the Olympic athletes 
and medical staﬀ . The Johnson & Johnson 
Beijing Science Center, built in 2005 to 
train medical professionals from the 
region, helped 80 Chinese physicians and 
2,000 medical personnel prepare for the 
Games. It remains a functioning training 
facility, supporting the growing health care 
infrastructure in China. 
 “The Beijing 2008 Olympic Games 
was a great opportunity to enhance our 
reputation in China, help our businesses 
grow faster, build deeper relationships 
with the government and people of 
China, and make Johnson & Johnson 
M O T H E R S  S H A R I N G  Onkita and Chasena are mothers who met online in BABYCENTER® 
India chat boards after the parenting site launched there in 2007. An example of how 
Johnson & Johnson considers market-speciﬁ c needs, each BABYCENTER® site around the 
world uses local editors and medical experts to provide for its community’s needs.
a more attractive place to work,” says 
Owen Rankin, Vice President of Corporate 
Equity, Johnson & Johnson.  
 Meanwhile, for Johnson & Johnson, 
China has become a center of research 
and development for new and aﬀ ordable 
products that address consumer 
needs in emerging markets. In 2007 
Johnson & Johnson opened the Emerging 
Markets Innovation Center in Shanghai. 
One of its ﬁ rst successes was the 2008 
launch of JOHNSON’S® Baby Long 
Protecting Cream, which addresses the dry 
skin that Chinese babies can experience 
in cold weather. The team used local 
market research, natural ingredients and a 
competitively priced 25-gram package to 
meet the needs of China’s emerging market.
TRAINING HEALTH CARE 
PROFESSIONALS
In other emerging markets, needs are more 
basic—the training that will allow health 
care professionals to provide the best 
possible care for the needs of the market. 
 For example, in 2008 a professional 
education center was established in 
Russia, where such education can impact 
care provided for cardiovascular disease, 
which causes just over half of all deaths 
in the country. In a unique partnership, 
Johnson & Johnson Medical Russia, along 
with Janssen-Cilag, worked with the Russian 
Ministry of Health to achieve a professional-
education goal by creating the Russian 
Center for Professional Education in Kazan. 
The center has the capacity to train up to 
3,000 physicians a year; two more training 
centers in Russia are being planned. 
 “By training health care professionals 
and increasing their knowledge of surgical 
procedures, we can impact the quality 
of care for patients,” says Alex Gorsky, 
Worldwide Chairman of Surgical Care, 
Johnson & Johnson. “The training approach 
we’ve enhanced over the years oﬀ ers a model 
that we’re adapting across many of our 
medical devices and diagnostics companies.”
 The Johnson & Johnson Vision Care 
Institute, LLC is providing important 
training and information for eye care 
professionals in 11 cities, including 
Shanghai, Dubai and Bangkok, and plans 
to continue its global expansion. Also, the 
Johnson & Johnson Diabetes Institute, LLC 
is active globally, launching in four markets 
last year. In all, Johnson & Johnson has more 
than 20 professional education centers 
around the world.
D E V E L O P I N G  N E W  M A R K E T S
76617_L1_r2.indd   29 5/22/09   12:23:19 AM
30
In many emerging markets, the poor are
disproportionately impacted by a range of
infectious diseases that can be devastating
in their eﬀ ect on individuals and whole
societies. Johnson & Johnson has a strong
commitment to develop and provide access
to infectious disease treatments for the
developing world, as well as substantial
philanthropy partnerships in developing
countries.1
For example, many of the more than
31 million people living with HIV/AIDS in the
developing world are in need of antiretroviral
therapies but have limited or no access
to these medicines. Mindful of the HIV
epidemic, our Tibotec subsidiary launched
its Global Access Program in 2006. Activities
currently target 20 priority countries in
sub-Saharan Africa, where 75 percent of the
world’s AIDS-related deaths occurred in 2007,
according to UNAIDS.
The program is designed to provide
a sustainable source of our HIV/AIDS
medicines for patients in these markets
who need them. It generates neither proﬁ t
nor loss for the company. We provide
 who
technical support and a royalty-free license
to local generic manufacturers to make
and deliver our second-line treatment,
PREZISTA® (darunavir), at a price that is
signiﬁ cantly lower than developed-world
prices. We also provide education for health
care professionals and work to get new
compounds registered with regulatory
authorities as quickly as possible.
“Our work is not about market share,
competition or proﬁ t. It’s about ﬁ nding ways
to address the needs of patients who are
dying because they are not getting the drugs
they need,” says Wlodek Kubiak, formerly
Vice President, Worldwide Access Programs,
Virology.
In addition to partnerships with generic
manufacturers, Tibotec has developed a
medicine for the most common side eﬀ ect
of HIV/AIDS, oral thrush, and distributes it
widely in Africa. Also, the company has given
a royalty-free license and other support to the
International Partnership for Microbicides
to develop, manufacture and distribute one
of our compounds as a vaginal microbicide to
prevent HIV transmission in resource-poor
countries.
Another of our companies, Transform
Therapeutics, is working with the Gates
Foundation’s Grand Challenges project
to develop product formulations that
will make it possible to distribute heat-
sensitive therapeutics, such as vaccines and
some medicines, without refrigeration in
developing countries.
Tibotec is also working toward a
collaboration to enhance development,
manufacturing and distribution of a
tuberculosis compound. This will be the ﬁ rst
new treatment in 40 years for multi-drug-
resistant tuberculosis, a devastating problem
in many developing countries.
“At Johnson & Johnson, patients are at
the center of everything we do,” said Paul
Stoﬀ els, head of Research and Development
for our Pharmaceuticals group and formerly
a physician working in the Congo. “As we
continue to forge new partnerships and
engage in new collaborations, we never lose
sight of our mission to care for the world,
one patient at a time.”
B U S I N E S S
Distributing Hope & Help
A R O U N D  T H E  W O R L D  We’re focused on
making life-changing, long-term diﬀ erences
in the prevention and treatment of HIV/AIDS.
Our virology franchise continues to grow as
we discover, develop and provide access to
medicines like PREZISTA® (darunavir) and
INTELENCE™ (etravirine), as well as new
medicines for TB and other diseases. And our
involvement in community-based programs,
such as mothers2mothers in South Africa,
continues to touch lives—like those of Kangela
and her son. Learn more at jnj.com/ourstories.
At the same time that many people in emerging markets have a newfound
sense of security and comfort, there are still many others who live in
dire poverty and face insurmountable health care needs. Eﬀ orts such as
our Tibotec Global Access Program oﬀ er hope and help.
1 See www.jnj.com/connect/caring/corporate-giving.
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businesses are not energy-
intensive. 
 The most potentially 
signiﬁ cant physical risk to our 
business resulting from climate 
change in the next decade is 
an extreme weather event 
that could result in the closing 
of a manufacturing facility, 
disruption of the supply chain 
or loss of ﬁ nished product 
inventory. Given our geographic 
distribution, our Puerto Rico 
operations appear to be at the 
highest risk for this possibility.
 We have evaluated increases 
of up to 100 percent of total 
energy costs for all facilities 
worldwide. The cost of energy 
as a percent of sales has been 
used as an indicator of business 
impact. We do not have data 
to identify embedded energy 
costs throughout our business, 
but based on those for which 
we have direct control, we 
estimate that the total cost is no 
more than 2 percent of sales. A 
doubling of energy costs for all 
direct and embedded energy 
would represent 4.0 percent of 
sales. We do not consider this to 
be a signiﬁ cant ﬁ nancial risk to 
the company. 
 Based on our energy- 
MANAGEMENT OVERVIEW 
The economic success of 
Johnson & Johnson depends 
upon our track record of 
capitalizing on opportunities as 
well as addressing potential risks.  
The stories on pages 26 to 29, “A 
Focus on Wellness & Prevention” 
and “Developing New Markets,”  
give readers a sense of two 
exciting opportunities for growth. 
 We also recognize that our 
economic performance can 
be impacted by marketplace, 
economic, environmental, social, 
political, ﬁ nancial and other 
risks. Some of these risks can be 
modulated by the company, but 
others, such as macroeconomic 
conditions, are not easily 
inﬂ uenced. 
 Still, we have robust 
approaches at multiple levels 
of the Company for managing 
risks.  Legal, ﬁ nancial, operational, 
compliance and reputational 
risk are led by individuals at the 
highest levels of the enterprise.  
The Company also employs 
multiple checks and balances 
within the organizational units.
 Our strong risk management 
systems have enabled 
Johnson & Johnson to deliver 
solid growth through all types 
Business
Performance
B U S I N E S S
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of economic cycles while also 
maintaining our triple-A credit 
rating.
 Our annual report contains 
signiﬁ cant details of our ﬁ nancial 
performance. Information 
summarized here addresses 
economic indicators included in 
the Global Reporting Initiative, 
such as the ﬁ nancial implications 
of climate change, potential 
risks to meeting deﬁ ned beneﬁ t 
plan obligations and local hiring 
practices.
RISKS DUE TO 
CLIMATE CHANGE
We have evaluated the risks 
posed to the organization by 
climate change as part of our 
involvement in the Carbon 
Disclosure Project (CDP). 
We believe regulatory risks 
could include increased 
energy costs due to taxes and 
renewable-energy directives; 
increased costs associated 
with tracking and managing 
climate change issues; and 
costs associated with increased 
investment in CO2 reduction 
projects. These impacts are
 not anticipated to be 
material to the cash ﬂ ow of 
Johnson & Johnson, as our 
reduction eﬀ orts in place 
since 1975, we feel we have 
an excellent energy-eﬃ  ciency 
proﬁ le and are well-positioned 
to compete in an energy- and 
carbon-constrained economy.1 
DEFINED BENEFIT PLAN 
OBLIGATIONS
The structure of retirement 
plans oﬀ ered to employees is 
in the form of a deﬁ ned 
beneﬁ t plan (a Pension 
Savings Plan) and other 
beneﬁ ts, including a voluntary 
401K.2 Johnson & Johnson 
maintains a trust to meet the 
pension plan liability. At the 
end of ﬁ scal year 2008, the 
projected beneﬁ t obligation 
was $11,923 billion, and the 
fair value of the assets equaled 
$7,677 billion, for a shortfall of 
$4,246 billion. Discretionary 
contributions are made when 
deemed appropriate to meet 
the long-term obligations 
of the plans. 
 The voluntary 401K—a 
2 For additional information on our 
ﬁ nancial performance, see www.
investor.jnj.com/annual-reports.cfm.
1 For more information, see our 
information on the CDP website at 
www.cdproject.net.
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deﬁ ned contribution plan—
is based on a minimum of
2 percent up to 6 percent
employee contribution from
each paycheck, matched at
75 percent by the employer.
There is no standing obligation,
as the obligation is met each
pay period once the funds
are disbursed into the 401K
trust. Our participation rate in
ECONOMIC
INDICATORS UNIT 2006 2007 2008
Sales
U.S. dollars,
millions 53,324 61,095 63,747
Percent
change over
previous year
5.6 14.6 4.3
Net earnings
U.S. dollars,
millions 11,053 10,576 12,949
Percent
change over
previous year
9.9 (4.3) 22.4
Share price
(end of calendar year)
U.S. dollars 66.02 67.38 58.56
Operating
companies
Number,
approximate 200 250 250
Employees Number,approximate 122,200 119,200 118,700
Research &
development
U.S. dollars,
millions 7,125 7,680 7,577
As percent of
sales 13.4 12.6 11.9
Effective income
tax rate
Percent of
income 24.2 20.4 23.5
Advertising costs
U.S. dollars,
billions 1.9 2.7 2.9
As percent of
sales 3.6 4.4 4.5
Charitable
contributions
U.S. dollars,
millions 544.8 509.9 510.3
As percent
of pre-tax
income
3.7 3.8 3.0
B U S I N E S S P E R F O R M A N C E
the 401K plan at the end of
2008 was 97 percent.
Our participation rate for
the U.S. Pension Plan is 100
percent—all employees who
are eligible (age 21 with at least
one year of service) participate,
since the Plan is provided at no
cost to our employees. Outside
the United States, pension plan
oﬀ erings vary and do not exist
WINNING
IN HEALTH
CARE
ACCELERATING
GROWTH IN
EMERGING
MARKETS
DEVELOPING
LEADERSHIP
AND TALENT
CAPITALIZING
ON
CONVERGENCE
B U S I N E S S  P R I O R I T I E S
in all countries. Our ability to
report on plan participation
outside the United States is
limited.
For more information, see
Note 13 and page 58 of our 2008
annual report at www.investor.
jnj.com/annual-reports.cfm.
HIRING LOCALLY
In a global, decentralized
business, hiring locally
helps us best meet customer
needs. Each subsidiary within
our business segments is,
with some exceptions,
managed by citizens of the
country where it is located.
Likewise, our operating
companies hire from the
communities in which we
do business.
T R A C K  R E C O R D  O F
P E R F O R M A N C E
76 CONSECUTIVE
YEARS OF SALES
INCREASES
25 CONSECUTIVE
YEARS OF ADJUSTED
EARNINGS INCREASES
46 CONSECUTIVE
YEARS OF DIVIDEND
INCREASES
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Selected
Recognitions
MOST ADMIRED COMPANIES,
2008, 2009
Fortune magazine recognized
Johnson & Johnson as ﬁ fth in its 2009
global ranking of corporate reputations. In
2008, Johnson & Johnson was ninth on the
American list and seventh for Global.
THE WORLD’S MOST
REPUTABLE COMPANIES, 2008, 2009
The Reputation Institute ranked
Johnson & Johnson as the second most
reputable company in the U.S. and the
ﬁ fth most reputable company in the world.
For 2009, Johnson & Johnson is ranked
ﬁ rst in the U.S. and third globally.
WORLD’S MOST RESPECTED
COMPANIES, 2008, 2009
The ﬁ nancial weekly Barron’s conducts an
annual survey of institutional investors,
rating the 100 largest public corporations
based on market capitalization in order of
the respect they have garnered from these
institutions. Johnson & Johnson was ranked
ﬁ rst on this list for the second year in a row.
TOP 10 COMPANIES FOR
EXECUTIVE WOMEN, 2008
Diversity Inc magazine ranked
Johnson & Johnson No. 1 on this list,
recognizing our Women’s Leadership
Initiative, now in its 13th year.
TOP 10 COMPANIES FOR
WOMEN EXECUTIVES, 2008
The National Association for Female
Executives selected Johnson & Johnson as
one of the Top 10 Companies for Women
Executives.
100 BEST COMPANIES FOR
WORKING MOTHERS, 2008
Working Mother magazine again named
Johnson & Johnson to this list, which
we have been included in every year
since the list was launched 23 years ago.
It recognizes our family-friendly policies
for ﬂ exible work, child care, maternity
and paternity leave, elder care and other
programs and services.
MOST SOCIALLY
RESPONSIBLE COMPANIES, 2008
The Boston College Center for Corporate
Citizenship honored Johnson & Johnson
as the third most socially responsible
company according to an analysis of data
collected in the Reputation Institute’s 2008
Global Pulse Study.
OUTSTANDING CORPORATE CITIZEN,
2008
America’s Blood Centers issued its ﬁ rst-
ever Outstanding Corporate Citizen seal
to Johnson & Johnson in celebration of
National Blood Donor Month.
MOST ADMIRED
PHARMACEUTICAL COMPANIES, 2008
Med Ad News, the pharmaceutical business
and marketing magazine, recognized
Johnson & Johnson as its most Admired
Pharmaceutical Company.
BENJAMIN FRANKLIN AWARD FOR
PUBLIC DIPLOMACY, 2008
The U.S. State Department recognized
Johnson & Johnson as the ﬁ rst corporate
recipient of this award for our work with
the Safe Kids Worldwide® program.  The
Company was a founding sponsor of the
program in 1987.
TOP 50 COMPANIES FOR
DIVERSITY®, 2008, 2009
This DiversityInc list is based on CEO
commitment, human capital, corporate
communications and supplier diversity.
Johnson & Johnson was ranked eighth
overall in 2008 and ﬁ rst in 2009.
BEST PLACES TO WORK
FOR GAY, LESBIAN, BISEXUAL AND
TRANSGENDER EQUALITY, 2009
For the fourth year, Johnson & Johnson
earned the top rating of 100 percent in
this annual survey administered by the
Human Rights Campaign Foundation.
The Equality Index recognizes employer
treatment of gay, lesbian, bisexual and
transgender employees and consumers.
SODALITAS SOCIAL AWARD, BEST
SUSTAINABILITY INITIATIVE, 2008
Johnson & Johnson Italy received this
National Award, which recognizes the best
social responsibility projects from companies
operating in the Italian market.  We were
particularly cited for our Healthy Planet 2010
goals, Energy Week and the International Day
of Energy Saving programs.
DOW JONES SUSTAINABILITY INDEX,
NORTH AMERICA, 2008
Johnson & Johnson stock has been included
in this index since 2000. The DJSI family
follows a best-in-class approach to identify
sustainability leaders in each industry.
MOST ADMIRED U.S. COMPANIES, 2009
In a study by Harris Interactive,
Johnson & Johnson has the best corporate
reputation among U.S. companies.
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FTSE4GOOD INDEX, 2008
Johnson & Johnson has been independently
assessed according to FTSE4Good criteria
and has satisﬁ ed the requirements to become
a constituent of this index, which identiﬁ es
companies that meet globally recognized
corporate responsibility standards.
SAFETY PERFORMANCE AWARD,
GOLD CLASS 1, 2008
The Malaysian Society presented this award to
Johnson & Johnson Malaysia for Occupational
Safety and Health.  It is the ﬁ fth consecutive
year the facility has been recognized for its
excellent safety performance.
CEO CANCER GOLD STANDARD™ AWARD,
2008
Johnson & Johnson is one of only 13
companies that have fully satisﬁ ed the
CEO Roundtable on Cancer’s requirements
for cancer-related practices. The Roundtable
was formed to make continual progress
on the elimination of cancer. Our CEO,
William C. Weldon, chairs it.
WALL STREET JOURNAL
ASIA 200 SURVEY, 2008
Johnson & Johnson was ranked 17th among
all companies and was the top health care
company among the leading 200 businesses in
Asia. Rankings were determined by hundreds
of business leaders, who evaluated companies
based on their innovation, long-term vision,
quality, corporate reputation and ﬁ nancial
reputation speciﬁ cally with regard to their
presence in Asia.
FACILITY OF THE YEAR, 2009
ISPE, INTERPHEX and Pharmaceutical
Magazine recognized Centocor Biologics
(Ireland) as its category winner in
Sustainability for 2009 Facility of the Year.
Centocor Biologics (Ireland) was chosen
from a ﬁ eld of 20 state-of-the-art facilities
in 12 countries.
TELL AWARD, 2008
Johnson & Johnson was presented with
the Tell Award for its long-term presence
and continued expansion in Switzerland.
This award acknowledges the continued
commitment of Johnson & Johnson to Swiss
economic growth.
TOP 50 HYBRID FLEETS, 2008
Automotive Fleet Magazine recognized
Johnson & Johnson Services, Inc. as the
No. 1 Top Commercial Fleet with 20.1 percent
hybrid vehicles in 2008. The number of hybrid
vehicles in the Company’s ﬂ eet increased
36 percent from the previous year.
STANDARD & POOR’S
NEW U.S. CARBON EFFICIENT INDEX,
2008
Johnson & Johnson made Standard & Poor’s
new U.S. Carbon Eﬃ cient Index, made up
of large-cap companies that have lower
carbon footprints when compared to the
overall S&P 500. Through 2008, the Carbon
Eﬃ cient Index had an average annual carbon
footprint that was 48 percent lower than
that of the S&P 500.
AWARD FOR BUSINESS EXCELLENCE,
2008
The Global Business Coalition (GBC)
recognized Johnson & Johnson as the
recipient of the 2008 GBC Award for
Business Excellence. Johnson & Johnson
partnered with mothers2mothers (m2m)
in South Africa to provide comprehensive
services for preventing mother-to-child
transmission of HIV.
G E N E R AT I N G  G R E E N  P O W E R Ibrahim Khadra, Staﬀ Engineer with Global Pharmaceutical Supply Group, LLC, Worldwide Engineering,
led a project to build a biomass boiler that uses woodchips from sustainable forests to fuel operations at Centocor Biologics (Ireland),
reducing the facility’s CO2 emissions and replacing natural gas. See Facility of the Year,  below.
ACCESS TO MEDICINE INDEX, 2008
Johnson & Johnson was ranked eighth
on this new index from the Access to
Medicine Foundation, designed to assess
pharmaceutical company eﬀ orts to provide
global access to medicine.
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O U R  C R E D O
We believe our ﬁrst responsibility is to the doctors, nurses and patients, to mothers
and fathers and all others who use our products and services. In meeting their needs,
everything we do must be of high quality. We must constantly strive to reduce our costs in order
to maintain reasonable prices. Customers’ orders must be serviced promptly and accurately.
Our suppliers and distributors must have an opportunity to make a fair proﬁ t.
We are responsible to our employees, the men and women who work with us
throughout the world. Everyone must be considered as an individual. We must respect their
dignity and recognize their merit. They must have a sense of security in their jobs.
Compensation must be fair and adequate, and working conditions clean, orderly and safe.
We must be mindful of ways to help our employees fulﬁ ll their family responsibilities.
Employees must feel free to make suggestions and complaints. There must be equal opportunity
for employment, development and advancement for those qualiﬁ ed. We must provide
competent management, and their actions must be just and ethical.
We are responsible to the communities in which we live and work and to the world community
as well. We must be good citizens—support good works and charities and bear our
fair share of taxes. We must encourage civic improvements and better health and education.
We must maintain in good order the property we are privileged to use,
protecting the environment and natural resources.
Our ﬁ nal responsibility is to our stockholders. Business must make a sound proﬁ t.
We must experiment with new ideas. Research must be carried on, innovative programs
developed and mistakes paid for. New equipment must be purchased,
new facilities provided and new products launched. Reserves must be created to provide for
adverse times. When we operate according to these principles, the stockholders
should realize a fair return.
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